Protocol: PJI001-02
A Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study 
to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults
[STUDY_ID_REMOVED]
Approval Date:  14-Feb-2019
T N P -2 0 9 2  T e n N or T hera pe utics Lt d.  
Pr ot oc ol PJI 0 0 1 -0 2  Pa ge 1 
TI T L E P A G E  
P R O T O C O L TI T L E: A P H A S E 2 , D O U B L E -B LI N D, R A N D O MI Z E D, 
M U L TI C E N T E R, P A R A L L E L, C O N T R O L L E D  S T U D Y T O 
E V A L U A T E T H E S A F E T Y, T O L E R A BI LI T Y, P H A R M A C O KI N E TI C S , 
A N D E F FI C A C Y O F T N P -2 0 9 2 T O T R E A T A C U T E B A C T E RI A L S KI N 
A N D S KI N S T R U C T U R E I N F E C TI O N  I N A D U L T S 
Pr ot oc ol N u m ber: P JI 0 0 1 -0 2  
A me n d me nt N u m ber: 1  
C o m p o u n d N u m ber: T N P -[ADDRESS_765123] u d y P h ase: 2  
S h ort Title: S afet y , T ole r a bilit y, P h ar m ac o ki neti cs , a n d Effic ac y of T N P -[ADDRESS_765124] ure I nfecti o n  
S p o ns or N a me: Te n N or T her a pe utics  Li mite d  
Le g al Re gister e d A d dress: [ADDRESS_765125], B uil di n g B 2, S uite 7 1 1  
S uz h o u I n d ustri al P ar k  
S uz h o u, C hi n a 2 1 5 1 2 3  
Re g ul a t or y A ge nc y I de ntifier N u m ber  
Re g ul at or y A ge nc y File  I de ntif yi n g #  
I N D: 
A p pr o v al D ate  Ori gi n al P r ot oc ol : Se pte m be r  16, 2 0 1 8  
A p pr o v al D ate A me n de d Pr ot oc ol: Fe br u ar y 1 4, 2 0 1 9  
T his d oc u me nt is t he c o nfi de ntial p r o pert y of T E N N O R T H E R A P E U TI C S  LI MI T E D . N o 
part of it ma y be tra ns mitte d, re pr o d u ce d, p u blis he d, or use d b y ot her pers o ns wit h o ut pri or 
writte n a ut h oriz ati o n fr o m T E N N O R T H E R A P E U TI C S  LI MI T E D . C CI 
T N P -2 0 9 2  T e n N or T hera pe utics Lt d.  
Pr ot oc ol PJI 0 0 1 -0 2  Pa ge 2 
 
   S p o ns or Si g n at or y:  
 
 
 
 
 
 
 
 
 
 
 
  Date  
 
  Date  C CI 
C CI 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 3 
 
   INVESTIGATOR SIGNATURE [CONTACT_44561]:  Phase 2, Double -Blind, Randomized, Multicenter, Parallel, Controlled 
Study to Evaluate the Safety,  Tolerability, Pharmacokinetics,  and Efficacy of TNP -2092 
to Treat Acute Bacterial Skin and Skin Structure Infection in Adults   
 
 
Signature [CONTACT_581923]  
T N P -2 0 9 2  T e n N or T hera pe utics Lt d.  
Pr ot oc ol PJI 0 0 1 -0 2  Pa ge 4 
 
   M E DI C A L M O NI T O R N A M E A N D C O N T A C T I N F O R M A TI O N  
  
  
  
  
 
  C CI 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 5 
 
   PROTOCOL AMENDMENT SUMMARY OF CHANGES  
DOCUMENT HISTORY  
Amendment  Date  
Amendment 1  14 February 2019  
Amendment 1 Approval Date ( 14 February  2019)  
The TNP -2092 IV 450 mg dose was omitted from the original protocol and the 
randomization scheme was revised from 1:1:1 to 2:1 TNP -2092 (300 mg) IV versus 
vancomycin  (1g) IV to reflect the change. This change was made to comply with an FDA 
request. Moreover, clarification on the timing and type of physical examinations and 
laboratory tests was made and typographical errors were corrected. Use of the local and 
central laboratories was clarified  and a list of prohibited medications was provided.  
A description of  substantive changes to the protocol are presented as follows:  
Section No. and Name  [CONTACT_11029]  
1.[ADDRESS_765126] 
omission  Remove redundant table  
4.1 Overall Design  Dose omitted and 2:1 randomization 
added , omitted table, hyperlink 
added to identical table,  To match current study design  
and remove redundant table  
4.2 Scientific Rational e … Dose omitted  Match dose regimen  
4.3 Justification for Dose  Dose omitted and added nonclinical 
data Match dose regimen  and provide 
support for dose regimen  
4.3.2  Clinical Data  One treatment arm removed  Match dose regimen  
5.1 Inclusion Criteria  Inclusion criteria (#3) revised   Descri be skin lesion 
measurement  and clarif y surgical 
procedures.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 6 
 
   Section # and Name  [CONTACT_11029]  
5.2 Exclusion Criteria  Added e xclusion criteria  
(Section  5.2) for body mass index 
≥30 kg/m2 (#1), list prohibited  
concomitant  medications (#13),  
modified liver test criteria  (#6) and 
added contraindications for 
fluoroquinolone use specified  (#8), 
and d eleted lesion description  
(former #10p)  To refine  patient population  
6.1 Study Interventions 
 Administered   2:[ADDRESS_765127] storage , and remov e 
redundant table   
6.4 Measures to Minimize 
 Bias 2:1 randomization added  Match current study design  
6.6.2  Prohibited Medications  Text to add  prohibited medications  
modified  Match text from prescribing 
information for approved 
fluoroquinolone (moxifloxacin) 
and rifamycin (rifa mpin ) 
6.6.3  Adjunctive Therapy  Text for surgical intervention s 
added   Clarify use of  surgical 
intervention  
6.6.4  Rescue Medication  Text for rescue medication and 
premature discontinuation of study 
intervention  added  Clarify use of rescue 
medications  
8.2.1  Physical Examinations  Day 1 exam omitted  Clarify timing of exam  
8.2.4  Clinical Safety 
 Laboratory  
 Assessments  Text for central and local laboratory 
assessment  separated   Clarify use of local and central 
laboratory assessments  
8.4.1  Clinical Response and 
 Table 8  (now Table 6) “No baseline gram -positive 
organisms for treatment of 
ABSSSI”  statement deleted  Statement untrue  
8.4.2  Microbiologic 
 Evaluation  Text regarding cellulitis  added  Clarify tissue collection from 
cellulitis lesions  
8.6 Pharmacokinetics  One treatment arm omitted  Dose omitted  
9.0 Statistical Considerations  One treatment arm omitted  Dose omitted  
9.2 Sample Size 
 Determination  New responder rate calculation 
added  for randomization  Randomization change d  
9.6 Safety Analyses  One treatment arm omitted  Dose  omitted  
9.8 Pharmacokinetic 
 Analyses  One treatment arm omitted  Dose omitted  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 7 
 
   Section # and Name  [CONTACT_11029]  
9.9 Handling of Dropouts…  “No baseline gram -positive 
organisms for treatment of 
ABSSSI”  statement deleted  Statement untrue  
10.2 Clinical Laboratory 
 Tests  Table  11: HIV testing  deleted ; 
allowed urine and serum pregnancy 
test type , and added measurement of 
haptoglobin  Clarif y laboratory  assessments  
including HIV  and pregnancy , 
and added haptoglobin 
measurements   
10.4 Prohibited Medications  Added new section with table of 
prohibited medications (Table 20) Response to request for  new 
Exclusion Criteria #13  
10.5 Pharmacokinetic 
 Sample … (previously 
 Section 10.4)  One treatment arm omitted  Treatment arm and dose  omitted  
10.[ADDRESS_765128]  Match protocol abbreviations  
10.7 Contraceptive Guidance 
 and ….  Pregnancy Report Form used to 
follow -up pregnancy outcome.  Clarify where pregnancy 
outcome should be documented  
11 Refe rences Prescribing information for 
moxifloxacin  (2016 ) added and 
prescribing information for rifam pin 
updated  (2019 ) Needed in response to prohibited 
concomitant medications list 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 8 
 
   TABLE OF CONTENTS  
INVESTIGATOR SIGNATURE [CONTACT_1783] ................................ ................................ .......... 3 
TABLE OF CONTENTS  ................................ ................................ ................................ ..8 
TABLE OF TABLES  ................................ ................................ ................................ .......10 
TABLE OF FIGURES  ................................ ................................ ................................ .....11 
1 PROTOCOL SUMMARY  ................................ ................................ ....................... 12 
1.1 Synopsis  ................................ ................................ ................................ ................. 12 
1.2 Schema  ................................ ................................ ................................ .................. 17 
1.3 Schedule of Activities  ................................ ................................ ........................... 17 
2 INTRODUCTION  ................................ ................................ ................................ ....20 
2.1 Study Rationale  ................................ ................................ ................................ ....20 
2.2 Background  ................................ ................................ ................................ .......... 20 
2.2.1  Nonclinical Data  ................................ ................................ ............................. 21 
2.2.2  Microbiology Data  ................................ ................................ ......................... 22 
2.2.3  Single -Dose and Multiple -Dose Studies in Healthy Subjects  ..................... 22 
2.3 Benefit/Risk Assessment  ................................ ................................ ...................... 23 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ......... 24 
4 STUDY DESIGN  ................................ ................................ ................................ ......24 
4.1 Overall Design  ................................ ................................ ................................ ......24 
4.2 Scientific Rationale for Study Design  ................................ ................................ .25 
4.3 Justification for Dose  ................................ ................................ ........................... 26 
4.3.1  Nonclinical Data  ................................ ................................ ............................. 27 
4.3.2  Clinical Data  ................................ ................................ ................................ ...27 
4.4 End of Study Definition  ................................ ................................ ....................... 28 
5 STUDY POPULATION  ................................ ................................ ........................... 28 
5.1 Inclusion Criteria  ................................ ................................ ................................ .28 
5.2 Exclusion Criteria  ................................ ................................ ................................ 30 
5.3 Lifestyle Considerations  ................................ ................................ ...................... 32 
5.4 Screen Failures  ................................ ................................ ................................ .....32 
6 STUDY INTERVENTION  ................................ ................................ ...................... 32 
6.1 Study Interventions Administered  ................................ ................................ .....32 
6.2 Criteria for Intravenous to Oral Treatment Switch  ................................ ......... 34 
6.3 Preparation/Handling/Storage/Accountability  ................................ ................. 34 
6.3.1  IV Antibiotic  ................................ ................................ ................................ ...34 
6.3.2  Oral Antibiotic  ................................ ................................ ............................... 35 
6.4 Measures to Minimize Bias: Randomization and Blinding .............................. 35 
6.5 Study Intervention Compliance  ................................ ................................ .......... 36 
6.6 Concomitant Therapy  ................................ ................................ .......................... 37 
6.6.1  Other Medicati on Therapy  ................................ ................................ ........... 37 
6.6.2  Prohibited Medications and Medications Requiring Special 
Consideration  ................................ ................................ ................................ .37 
6.6.3  Adjunctive Therapy  ................................ ................................ ....................... 37 
6.6.4  Rescue Medication  ................................ ................................ ......................... 38 
6.7 Dose Modification  ................................ ................................ ................................ 38 
6.8 Intervention After the End of the Study  ................................ ............................ 38 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 9 
 
   7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ............................... 38 
7.1 Discontinuation of Study Intervention  ................................ ............................... 38 
7.2 Participant Discontinuation/Withdrawal from the Study ................................ [ADDRESS_765129] to Follow -up ................................ ................................ ................................ .39 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................... 39 
8.1 Protocol Adherence  ................................ ................................ .............................. 39 
8.2 Safety Assessments  ................................ ................................ ............................... 41 
8.2.1  Physical Examinations  ................................ ................................ ................... 41 
8.2.2  Vital Signs  ................................ ................................ ................................ .......41 
8.2.3  Electrocardiograms ................................ ................................ ........................ 41 
8.2.4  Clinical Safety Laboratory Assessments  ................................ ...................... 41 
8.3 Adverse Events and Serious Adverse Events  ................................ .................... 43 
8.3.1  Period and Frequency for Collecting AE and SAE Information  .............. 43 
8.3.2  Method of Detecting AEs and SAEs  ................................ ............................. 43 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ .......... 43 
8.3.4  Regulatory Reporting Requirements for SAEs  ................................ ........... 44 
8.3.5  Pregnancy  ................................ ................................ ................................ .......44 
8.3.6  Death Events  ................................ ................................ ................................ ...45 
8.3.7  Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ................................ ................................ ............ 45 
8.4 Efficacy Assessments  ................................ ................................ ........................... 45 
8.4.1  Clinical Response  ................................ ................................ ........................... 45 
8.4.2  Microbiologic Evaluation  ................................ ................................ .............. 47 
8.5 Treatment of Overdose  ................................ ................................ ........................ 51 
8.6 Pharmacokinetics  ................................ ................................ ................................ .51 
8.7 Pharmacodynamics  ................................ ................................ .............................. 52 
8.8 Genetics  ................................ ................................ ................................ ................. 52 
8.9 Biomarkers  ................................ ................................ ................................ ........... 52 
8.10  Health Economics/Medical Resource Utilization and Health Economics  ......52 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ....52 
9.1 Statistical Hypotheses  ................................ ................................ .......................... 52 
9.2 Sample Size Determination  ................................ ................................ ................. 52 
9.3 Populations for Analyses  ................................ ................................ ..................... 52 
9.4 Analysis of Study Populations and Participant Characteristics  ...................... 56 
9.5 Study Intervention Exposure  ................................ ................................ .............. 56 
9.6 Safety Analyses  ................................ ................................ ................................ .....56 
9.7 Efficacy Analyses – Secondary Endpoints  ................................ ......................... [ADDRESS_765130] Approval  ................................ .......................... 65 
10.1.11  Publication Policy ................................ ................................ ........................... 65 
10.1.12  Data Management and Monitoring  ................................ .............................. 65 
10.2  Clinical Laboratory Tests ................................ ................................ .................... 66 
10.3  Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ................... 66 
10.3.1  Definition of AE ................................ ................................ .............................. 66 
10.3.2  Definition of SAE  ................................ ................................ ........................... 68 
10.3.3  Recording and Follow -Up of AE and/or SAE  ................................ ............. [ADDRESS_765131] of Abbreviations  ................................ ................................ ........................... 75 
10.7  Contraceptive Guidance and Collection of Pregnancy Information  ............... 76 
11 REFERENCES  ................................ ................................ ................................ ......... 78 
 
TABLE OF TABLES  
Table  1 Objectives and Endpoints ................................ ................................ ........ 13 
Table  2 Treatment Arms  ................................ ................................ ....................... 16 
Table  3 Schedu le of Activities  ................................ ................................ ............... 18 
Table  4 Preparation of Reconstituted TNP -2092 and Vancomycin  .................. 33 
Table  5 Clinical Response Definitions – Programmatic Determination  ........... 46 
Table  6 Clinical Response Definitions – Investigator’s Assessment  ................. 47 
Table  7 Microbiologic Outcome Categories  ................................ ........................ 50 
Table  8 Emergent Infections  ................................ ................................ ................. 50 
Table  9 Populations for Analysis  ................................ ................................ .......... 54 
Table  10 Efficacy Evaluations by [CONTACT_581882]  ................................ ........ 57 
Table  11 Protocol -Requ ired Safety Laboratory Assessments  ............................. 66 
Table  12 Definition of AE ................................ ................................ ........................ 67 
Table  13 Events Meeting the AE Definition  ................................ .......................... 68 
Table  14 Definition of SAE  ................................ ................................ ..................... 69 
Table  15 Recording and Follow -Up of AE and/or SAE and Assessment of Intensity
................................ ................................ ................................ .................... 70 
Table  16 Assessment of Adverse Event/Serious Adverse Event Intensity  .......... [ADDRESS_765132] of Prohibited Concomitant Medications  ................................ ........ 73 
Table  21 Pharmacokinetic Sample Schedule  ................................ ........................ 74 
 
TABLE OF FIGURES  
Figure  1 Overview of Treatment Duration  ................................ ........................... 14 
Figure  2 Overview of Study Design  ................................ ................................ .......17 
Figure  3 Overview of Analysis Populations  ................................ .......................... 55 
 
T N P -2 0 9 2  T e n N or T hera pe utics Lt d.  
Pr ot oc ol PJI 0 0 1 -0 2  Pa ge 1 2  
 
   1 P R O T O C O L S U M M A R Y  
1. 1  S y n o psis  
Pr ot oc ol Title : A P hase 2, D o u ble -Bli n d, R a n d o miz e d , M ultic e nter, Par allel, C o ntr olle d  
St u d y t o E val u ate t he Safet y, T ol era bilit y, P har m ac o ki neti cs , a n d Effi cac y  of T N P -[ADDRESS_765133] ur e I nfe cti o n  i n A d ult s 
S h ort Title: Safet y , T oler a bilit y, P har ma c o ki netics a n d Effica c y of T N P -[ADDRESS_765134] ure I nfe cti o n  
R ati o n ale:  
A nti bi oti c resista n ce p oses a seri o us t hre at t o p u blic healt h w orl d wi d e. Researc h eff orts 
i n rece nt years ha ve b e c o m e i ncr easi n gl y g eare d t o war d  disc o veri n g a n d de vel o pi n g ne w 
classes of a nti bi oti cs wit h m o des of acti o n disti nct fr o m t h ose of esta blis he d a g e nts a n d 
acti vit y a g ai nst resist a nt strai ns. A d diti o nal n o vel a nti bi oti c c h oi ces are ne e de d t o trea t 
bacterial i nfecti o ns  s us pe cte d or c o nfir me d  t o be c a use d b y a nti bi otic -r esista nt , 
gra m -p ositi v e  pat h o g e ns  (e g, met hicilli n -r esista nt St a p hyl oc oc c us a ure us  [ M R S A]) .  
T N P -[ADDRESS_765135] ur e 
i nfecti o ns ( A B S S SI ) s us pecte d or c o nfir me d t o be ca use d b y a nti bi otic r esista nt gr a m -
p o siti ve pat h o ge ns, a n d bi ofil m -ass ociate d f or ei g n b o d y i nfecti o ns,  i ncl u di n g t h ose 
me dic ate d b y m ulti dr u g -resista nt pat h o ge ns.  
O bjecti ves a n d E n d p oi nts : 
T his is t he first st u d y i n w hic h T N P -[ADDRESS_765136] u d y, p har ma c o ki neti cs ( P K ) a n d efficac y will 
c o m prise  sec o n d ar y  o bjecti ves. T h e o bje cti v es a n d e n d p oi nts are prese nte d i n  Ta ble  1. C CI 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 14 
 
   All p articipants wi ll be treated w ith IV study intervention  for a minimum of 3  days 
(6 doses) .  
Figure  1 Overview of Treatment Duration  
 
IV = intravenous; R x = treatment  
Note: The duration of the trea tment period (IV or IV plus oral switch, if applicable ) is a minimu m of 7 days 
and a maximum of 14  days. Participants will be treated with IV study intervention for a minimum of 3 days 
(6 doses) . Upon meeting protocol -specified switching criteria ( Section 6.2), participants will continue 
treatment of ABSSSI with a commercially -available, open -label, oral antibiotic selected by [CONTACT_093].  
 
Upon meeting protocol -specified swi tching criteria ( Section  6.2), participants will 
continue treatment of ABSSSI with a commercially -available, open -label, oral antibiotic 
selected by [CONTACT_093]. An overview of the study design is presented in Section  4 
and the Schedule of Activities is presented in Section  1.3. 
Eligible p articipants will be random ized ( 2:1) to 1 of 2 treatment arms: TNP -2092 
300 mg IV q12h or vancomycin 1 g  IV q12h . Randomization will be stratified by 
[CONTACT_581883]. The types of eligible 
ABSSSI include cellulitis/ erysipelas, wound infections, and  major cutaneous abscesses; 
however, participants with major cutaneous absces s should not comprise >30% of 
randomized population . Participants with a minimum ABSSSI lesion surface area of 
[ADDRESS_765137] recognized methods. All bacteria isolated from an 
adequate local ABSSSI site specimen or blood culture at the local laboratory will be sent 
to a designated central laboratory for confirmation of species identification and 
antimicrobial susceptibility testing. Microbiologic methods are described in Section  8.4.2  
and more details are presented in the laboratory m anual.  
If local antimicrobial susceptibility testing of a baseline pathogen indicates possible 
non-susceptibility to study intervention (eg, intermediate susceptibility or resistance to a 
fluoroquinolone, rifamycin,  and/or glycopeptide) but the participant  is stable or clinically 
improving, the participan t should remain on study intervention at the investigator’s 
discretion. In these  cases, the inve stigator should discuss each  situation  with the medical 
monitor before discontinu ation from study intervention . 
Screening assessments to determine study eligib ility will be performed within [ADDRESS_765138] dose of study  intervention is administered. Intravenous study intervent ion 
may be administered in a hospi[INVESTIGATOR_581871]; outpatient  administration 
of IV study intervention  is limited to participants who are clinically stable and have 
adequate home support with reliable transportation to and from the hospi[INVESTIGATOR_17399] l or clinic, as 
described in the Pharmacy Manual.  
Day [ADDRESS_765139] day of s tudy intervention ; subsequent study days are consecutive 
calendar days. For purposes of analysis, study assessments will be performed during the 
treatment pe riod on Day 1, Day 2,  at early assessment (EA) 48 to 72 hours after IV 
treatment is started, at end of IV  (EOIV , 3 to 14 days after IV treatment is started ) at end 
of treatment (EOT, after  a minimum of 7  days up to 14  days of intervention, IV or  IV 
plus oral switch , if applicable ), at posttreatment evaluation ( PTE, 7 to 14 days after 
EOT ), and at long -term follow -up (LTFU , 20 to 25  days after EOT ) (Figure  2). 
The primary endpoint is assessment of safety and tolerability: incidence of adverse events 
(AEs ), vital signs laboratory data, and ECG findings, and a qualitative assessment of 
local tolerability  (including  local infusion site rea ction and thrombotic events ) measured 
throughout the st udy. Secondary endpoints comprise  PK (first dose  and at EOIV  
treatment ) and efficacy assessments ( programmatic clinical response at EA  aligns with 
the current FDA guidance  [2013 ]). Secondary efficacy endpoints  also include the  
investiga tor assessme nts of clinical response at designated timepoints and 
microbiological responses at PTE . 
Number of Participant s: 
This protocol plans to enroll 120  participants who meet study entry criteria who will be 
randomly assigned to 1 of 2 treatment arms  in a 2:1 ratio as presented in Table  2. A 
sample size of 80 participants who receive TNP -2092  is deemed sufficient to provide an 
initial assessment of safety and PK data to inform the future development of TNP -2092.  
Intervention Arm s and Duration:  
The total  duration of th e study is up to [ADDRESS_765140] 3 days  (6 doses)  of IV intervention  and a 
minimum of 7  days and up to 14 days of treatment , a PTE visit 7 to 14  days after the 
EOT, and a LTFU visit comprising a telephone  call, 20 to 25  days aft er the EOT  to 
monitor continuing AEs  and concomitant medications  (Figure  2). 
The 2 treatme nt arms are presented  in Table  2. 
Table  2 Treatment Arms  
Arm  Study Intervention, Dose,  Duration  Assigned Treatment 
Intervention  
Concentration  Planned 
Number of 
Participants  
A TNP -2092 300 mg IV q12h  Day 1 up to 
Day 14 (at least 3  days [6 doses] required)  TNP -2092 (lyophilized red 
orange powder)  300 mg in 
200 mL D5W  (1.5 mg/mL) 
for IV infusion  80 
B Vancomycin  1 g IV q12h , Day 1 up to Day  14 
(at least 3 days [6 doses] required)  Vancomycin 1 g in 200 mL  
D5W (5 mg/mL) for IV 
infusion  40 
IV = intravenous; q 12h = every [ADDRESS_765141] 3 days  (6 doses)  
of IV study intervention  provided oral  switch  criteria and procedures are met 
(Section  6.2). 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 17 
 
   1.2 Schema  
An overview of the study design is presented in Figure  2. 
Figure  2 Overview of Study Design  
 
 
EA = early assessment; EOIV = end of IV treatment; EOT = end of treatment; IV = intravenous; 
LTFU  = long-term follow -up; PO = oral; PTE = posttreatment evaluation; q12h = every 1 2 hours  
Note: Participants receive a minimum of 3 days (72 hours, 6 doses ) of IV study intervention. After 
72 hours , participants may begin oral antibiotic treatment upon meeting  protocol -specified criteria 
(Section  6.2). 
*EA ( [ADDRESS_765142] dose of IV intervention ) and EOIV  (at least [ADDRESS_765143] dose of IV intervention ) may occur simultaneously . EOT may be any  day after at least  7 days 
of treatment  initiation up to  14 days after treatment initiation.  
 
1.3 Schedule of Activities  
A Schedule of A ctivities is presented in  Table  3. 

TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 18 
   Table  3 Schedule of Activities  
Study Visit  Screening a Intravenous plus Oral Treatment Period b PTE d 
 LTFU e 
 
Day -1 Day 1b Day 2  EA c 
After 48 to 
72 h  EOIV  (+ 1)  
After 72 h  
up to Day 14  EOT c (+ 1) 
≥ Day 7 up 
to Day 14   7 to 14 Days 
after EOT  20 to 25 
Days after 
EOT  
Informed c onsent , demographics, 
medical/surgical history, 
inclusion/exclusion criteria , CrCl  f,g  X        
Randomization h  X       
Prior/concomitant medications i X X X X X X X X 
Physical exam/ focused physical exam  
j X  X X X X X  
Vital signs  k X X X X X X X  
12-lead ECG l X   X  X X  
Serum or urine p regnancy test m X     X   
Assess primary  ABSSSI site n X X X X X X X  
Investigator assessment of clinical 
response o     X X X  
Hematology/ chemistry/ urinalysis p X X X X X X X  
Administer study intervention up to 
14 days q  X   
ABSSSI specimen , Gram -stain  and 
culture , blood cultures  r,s X (X) (X) (X) (X) (X) (X)  
Record procedures (I&D) t (X) (X) (X) (X) (X) (X) (X) (X) 
PK sample collection u  X   X    
Thrombotic and local i nfusion  site 
reaction AE assessments   X X X X    
Adverse Events  X X X X X X X X 
AEs = adverse events,β -HCG = beta -human chorionic gonadotropin; BP = blood pressure; CrCl = creatinine clearance; EA = early assessment; ECG = electrocardiogram; EOIV = end of IV 
assessment; EOT = end of treatment; HR = heart rate; I&D = incision and drainage; IV  = intravenous; IWRS = interactive web response system; LTFU = long -term follow -up; 
PK = pharmacokinetic: PTE  = posttreatment evaluation ; SAE = serious adverse event  
a Screening assessments for study eligibility will occur within [ADDRESS_765144] day for administration of IV study intervention and subsequent days are calendar days. Participants will receive IV infusion at the hospi[INVESTIGATOR_25644] a minimum of 
3 days (6 doses) based on the investigator’s clinical judgment and after switching criteria are met ( Section  6.2). The duration of the treatment period (IV or IV plus oral switch, if 
applicable) is a minimum of [ADDRESS_765145] calendar day of study 
intervention (IV or IV plus oral switch, if applicable). Participants who prematurely discontinue study intervention or withd raw from the s tudy before EOT should have all EOT 
assessments performed on the day of withdrawal (+ 1 day).  
d Participants will attend the PTE 7 to 14 days after the EOT for collection of safety and efficacy data (clinical and microbio logical response [ Section  8.4.1  and Section  8.4.2 ]) . 
e Telephone contact [CONTACT_581884] [ADDRESS_765146] of care scre ening assessments are performed.( Section  10.1.4 ) 
g CrCl will be calculated according to Cockcroft -Gault ( Section  10.1.12 ). Participants with CrCl < 30  mL/minute will be excluded from the study.  
h All inclusion and exclusion criteria need to be met before rando mization on Day 1. All participants will be centrally assigned to randomized study intervention via IWRS ( Section  6.4) 
i All prior medications take n within 2  weeks before randomization will be recorded. All concomitant medications taken between Day 1 and EOT will be recorded t o LTFU  (Section  6.6). 
j A complete physical examination (ie, general appearance, head, ears, eyes, nose, throat, dentition, thyroid, chest [heart, lu ngs], abdomen, skin/soft tissues, neurological, extremities, 
 back, neck, musculoskeletal, lymph nodes) and height (screening only)  and weight will be performed at screening, EOIV, EOT, and PTE ( Section  8.2.1 ). Focused physical examinations 
 (chest [heart,  lungs], abdomen, skin , neurological and musculoskeletal examinations) are performed on Day 2, EA, and each subsequent day that IV treatment is adm inistered but not 
 including EOIV.  
k Vital signs comprises temperature [oral], pulse rate, respi[INVESTIGATOR_697], and blood pressure per formed at all visits except LTFU ( Section  8.2.2 ). 
l ECGs will be performed in triplicate within a 15 -minute period at screening, EA, EOT, and PTE ( Section  8.2.3 ). 
m Female participants of childbearing potential (<  2 years after menopause and not permanently sterile) must have a β-HCG pregnancy  test at baseline and EOT ( Section 8.3.5 ) 
n Direct evaluation of the primary ABSSSI site includes an assessment of the extent of infection as measured with a ruler (long est length by [CONTACT_581885]) and an 
assessment of local  signs and symptoms ( Section  8.4.1 ). 
o The investigator’s assessment of clinical response is defined in Table  6. 
p Laboratory assessments including hematology, coagulation, serum chemistry, and urinalysis testing will be performed to collec t safety data at all visits except LTFU . Screening/baseline 
 test samples will be collected  and sent to local laborator y (to confirm eligibility) and central laborator y (screening and subsequent testing)  (Section  8.2.4 , Section  10.2, and  
Table  11). 
q On Day 1, the first dose of study intervention should be administered as quickly as possible after eligibility criteria are m et. Participants receive an IV infusion over 60 minutes q12h f or 
a minimum of 3 days (6 doses) followed by a switch to a commercially -available, oral antibiotic (criteria described in Section  6.2) for the rema inder of the intervention, minimum 7 to 
14 days total.  
r Obtain appropriate ABSSSI site specimens from all subjects at screening and perform gram -stain and culture at the local laboratory The ABSSSI site specimen should be obtained 
before administration of  antibacterial therapy, whenever possible. Repeat testing is only required (X) if a previous culture was reported as positive, if clinically indicated, or if the 
participant is deemed a clinical failure (Section  8.4.1  and Section   8.4.2 ). 
s. Two sets of blood cultures (each set comprises 1 aerobic and 1 anaerobic tube from 2 separate venipuncture sites, for a total of 4 tubes) will be collected from all participants at 
screening. The blood  cultures should be obtained before administration of antibacterial therapy, whenever possible. Repeat testing is onl y required (X) if a previous blood culture was 
reported as positive, if clinically  indicated, or if the participant is deemed a clinical failure ( Section  8.4.1  and Section   8.4.2 ). 
t If required, s urgical procedures to treat ABSSSI (eg, I&D) should be performed , before the first dose of study intervention up to 24 hours  (Day 2)  after the first dose of study 
 intervention . After Day 2, surgical intervention will be captured  (X); however , subject evaluability in analysis populations may be affected (Section  6.6.3 ).  
u Blood samples will be collected for PK analysis on Day [ADDRESS_765147] a nt strai ns. A d diti o nal n o vel a nti bi o ti c c h oi ces are ne e de d t o treat  
bacterial i nfecti o ns s us pecte d or c o nfir me d t o be c a use d b y a nti bi otic -r esista nt gr a m -- p ositi ve 
pat h o ge ns , t he lea di n g ca use of ba cterial i nfecti o ns i n h u ma ns ( Va n  Hal, 2 0 1 1 ). T he C e nter 
f or Disease Co ntr ol esti mates t hat great er t ha n  [ADDRESS_765148] a p hyl oc o cc us a ure us  (M R S A ) i nfecti o ns a n d great er t ha n 1 1, 0 0 0  relat e d deat hs oc c ur 
a n n u all y  i n t he U nite d States . M ore o ver,  a n u n k n o w n b ut m uc h hi g h er n u m ber of less se vere 
i nfecti o ns re q uire treat me nt i n c o m m u nit y a n d healt h care setti n gs ( C D C, 2 0 1 3 ).  
T N P -[ADDRESS_765149] u g -r esista nt pat h o ge ns.  
2. 2  B ac k gr o u n d  
Te n N or  T hera pe utics Li mit e d ( T e n N or)  is de vel o pi n g T N P -[ADDRESS_765150] study in w hich TNP -2092 is administered to  participants with  ABSSSI  
suspected or confirmed to be caused by [CONTACT_152926] -positive pathogens . Safety and tolerability 
comprise  the primary objectives , and PK and efficacy comprise  the secondary objective s. 
The objectives and endpoints are presen ted in  Table  1. 
4 STUDY DESIGN  
4.1 Overall Design  
This P hase 2, double -blind, randomized, multicenter, parallel, controlled  study will be 
conducted to evaluate safety, tolerability , and PK of TNP -2092  300 mg IV q12h , and 
vancomycin 1 g IV q12h in adults with ABSSSI suspected or confirmed to be caused by 
[CONTACT_152926] -positive pathogens . The duration of t he treatment period (IV or IV plus oral switch , if 
applicable ) is a minimum of 7 days and a maximum of 14 days as presented in Figure  1. 
All participants will be treated with IV study intervention for a minimum of 3  days (6 doses).  
Upon meeting protocol -specified switching criteria ( Section  6.2), participants w ill continue 
treatment  with a commercially -available,  open-label , oral  antibiotic selected by [CONTACT_1275]. The Schedule of A ctivities is presented in Table  3 (Section  1.3). 
Participants who meet the entry criteria  (Section  5.1and Section  5.2) will be randomized 
(2:1) to 1 of 2 treatment arms: TNP -2092 300 mg IV q12h or vancomycin 1  g IV q12h  
(Table  2). Randomization will be stratified by [CONTACT_581886]  (Planned N  = 120, n = 80 for TNP -2092 arm A and n = 40 for 
vancomycin arm B). The types of eligible ABSSSI include cellulitis/erysipelas, wound 
infections, and major cutaneous abscesses ; however, participants with major cutaneous 
abscess should not comprise >  30% of randomized population . Partici pants with ABSSSI 
with a minimal  lesion surface area of 75  cm2 will be enr olled  (FDA Guidance, 2013 ). No 
prior antibiotic treatment for the current ABSSSI is permitted before enrollment in the study, 
and no other concomitant systemic or topi[INVESTIGATOR_581872]. If a 
participant enrolls and is subsequently found to have a gram -negative or anaerobic bacterial 
infection, they may remain in the study but may  be switched to an  appropriate antibiotic and 
will not be included in the modified intent -to-treat (mITT)  population (excludes all 
participants with gram -negative pathogens)  as described in Table  9. 
An adequate local ABSSSI site specimen must be collected from all participants with non -
cellulitis ABSSSI for microbiologic evaluation at baseline. Blood samples from local 
ABSSSI site specimens, and blood cultures from [ADDRESS_765151] ere d i n a h os pi[INVESTIGATOR_6879] o ut patie nt i nf usi o n ce nt er; o ut patie nt  a d mi nistrati o n of I V st u d y 
i nter ve nti o n  is li mite d t o p arti ci pa nts w h o are cli nicall y sta bl e a n d ha v e a de q uate h o m e 
s u p p ort wit h reli a ble tra ns p ortati o n t o a n d fr o m t he h os pi[INVESTIGATOR_581873] c, as descri be d i n t he 
P har mac y Ma n ual.  
Da y [ADDRESS_765152] da y of s t u d y i nter v e nti o n ; s u bse q ue nt st u d y da ys are c o nse c uti v e  cal e n dar 
da ys. F or p ur p os es of a nal ysis, st u d y assess me nts will be perf or me d d uri n g t he tr e at m e nt 
peri o d o n Da y 1, Da y 2, at earl y assess me nt ( E A) 4 8 t o 7 2 h o urs after I V treat me nt is start e d, 
at E OI V (a n y cale n dar da y u p t o Da y  1 4 ) at t he e n d of treat me nt ( E O T, after a mi ni m u m of 
[ADDRESS_765153] us oral s witc h , if a p pli ca ble ), at 
p osttreat me nt e val u ati o n ( P T E, 7 t o 1 4  da ys aft er E O T), a n d at l o n g -ter m f oll o w -u p ( L T F U, 
2 0 t o 2 5  da ys after E O T).  
Safet y assess me nts will b e perf or me d at e ac h visit fr o m scree ni n g t o L T F U as i n di cate d i n 
t he Sc he d ul e of A cti viti es ( Secti o n  1. 3 ). Safet y will be assess e d b y A Es, p h ysical 
e xa mi n ati o ns, vital si g ns, l a b orat or y e val uati o ns ( he mat ol o g y, c he mistr y, c oa g ulati o n, 
uri nal ysis), a n d E C G par a meters. Pri mar y P K para m eters are sec o n d ar y e n d p oi nts a n d  bl o o d 
sa m ples w ill b e o btai ne d f or a nal ysis  o n Da y 1 a n d E OI V visi ts a t desi g nat e d ti mes 
(Secti o n  1 0. 4 ).   
Cli nic al a ssess me nts  of t h e pri m ar y A B S S SI site  ( me as ure me nt of e xte nt of i nfecti o n a n d 
si g ns  a n d s y m pt o ms ) will oc c ur at eac h visit fr o m t h e scree ni n g visit t o P T E , w he n cli nicall y 
i n dica te d, or if t he partici p a nt is de e me d a cli nic al fail ure  (Secti o n  8. 4. 1 ). A B S S SI site 
s peci me n c ult ur es will be assess e d at scr ee ni n g,  w he n cli ni call y i n di cat e d, or if  t he 
partici pa nt is dee m e d a cli nic al fail ure. Bl o o d c ult ures will be assesse d at scre e ni n g wit h 
re peat testi n g if t he pre vi o us bl o o d c ult ure was r e p orte d as p ositi v e, w he n  cli nic all y i n dicate d 
or if  t he partici pa nt is dee me d a cli nic al fail ure  (Se cti o n  8. 4. 1 ). 
4. [ADDRESS_765154] ere d 
T N P -2 0 9 2 ( 3 0 0 m g q 1 2 h) a n d I V a d mi nist ere d va nc o m yci n ( 1 g q 1 2 h) i n a d ult p arti c i pa nts 
wit h A B S S SI. T he st u d y desi g n i nc or p orat es rec o m me n dati o ns fr o m t he U S F o o d a n d Dr u g 
A d mi nistrati o n 2 0 1 3 G ui da nc e f or I n d ustr y ( A B S S SI: De vel o pi n g Dr u gs f or Treat me nt) 
(F D A, 2 0 1 3 ). T he safet y a n d t ol era bilit y par a meters m o nit ore d d uri n g t he st u d y are 
well -esta blis he d m eas ures of safet y i n cli nical st u d y partici pa nts. Bl o o d sa m ples will be 
c olle cte d t o det er mi ne t he P K para m eters of T N P -[ADDRESS_765155] u d y p o p ulati o n.  T he sec o n d ar y e n d p oi nts of pr o gra m matic cli ni cal r es p o nse at E A ali g ns 
wit h t he c urr e nt F D A g ui da nce  (2 0 1 3 ). Sec o n d ar y efficac y e n d p oi nts als o i ncl u de t he 
i n vesti gat or assess me nts of cli nic al res p o nse at d esi g nate d ti me p oi nts a n d micr o bi ol o gical 
res p o nses at P T E.  
4. [ADDRESS_765156] u d y w he n t he L T F U visit  has  bee n c o m plet e d as s h o w n i n t he Sc he d ule of 
Acti vities ( Secti o n  1. 3 ). T he e n d of t he st u d y is defi n e d as t he date of t h e last visit f or t he last 
pa rtici pa nt i n t he st u d y.  
[ADDRESS_765157] y  as f oll o ws : 
A ge  
1.  A d ult m al e s or fe male s,  [ADDRESS_765158] 3  d a ys  
( 6 d oses) . Partici pa nts wit h 3 i nfe cti o n t y pes will be e nr olle d:  
a.  Cell ulitis/ er ysi pel as - a diff us e s ki n i nf ecti o n c hara ct erize d b y a s prea di n g ar ea of 
re d ness, e de ma, a n d/ or i n d urati o n  
b.  W o u n d i nfecti o n (tr a u matic or p osts ur gic al) - a n i nfe cti o n i n v ol vi n g s ki n a n d 
s u bc uta ne o us tiss ue, c h aract eriz e d b y p ur ule nt drai n a ge fr o m a w o u n d wit h 
s urr o u n di n g re d ness, e de ma, a n d/ or i n d urati o n  
c.  Maj or c uta n e o us a bscess: a n i nfe cti o n c hara cterize d b y a c oll ecti o n of p us wit hi n t h e 
der mis or dee p er t hat is acc o m pa ni e d b y re d nes s, e de ma, a n d/ or i n d urati o n  
 
3.  S ki n i nfecti o n wit h a lesi o n s urface area at l east 7 5 c m 2 (l o n gest l e n gt h a n d wi d est wi dt h 
per pe n dic ular t o t he le n gt h ma n u all y meas ure me nt wit h r uler). T he s urface area will be 
calc ulat e d b y m ulti pl yi n g t he le n gt h x wi dt h. T he l esi o n size will be m eas ure d b y are a of 
re d ness, e de ma, or i n d urati o n , w hi c he ver is g reat est .  C CI 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 29 
 
  For participants with more than 1 type of eligible lesion/wound or with multiple lesions 
of the same type, the investigator must clearly identify the lesion to be evaluated for 
study purposes. Surgical procedures to treat ABSSSI (eg, i ncision and  drainage  [I&D]) 
are permitted before the first dose of study intervention up to [ADDRESS_765159] 2  of the following local signs at the ABSSSI site : 
a.  Purulent or seropurulent drainage/dischar ge 
b. Erythema  
c. Fluctuance  
d. Heat/localized warmth  
e. Pain/tenderness to palpation  
f. Swelling/induration  
5. At least 1 marker of systemic inflammation:  
a. Fever or hypothermia (oral temperature ≥  38.0ºC or ≤  36.0ºC)  
b. White blood cell (WBC) count ≥10,000/mm3 or ≤4,000/mm3 
c. Immature neutrophils (bands) ≥15% irrespective of WBC count  
d. Presence of lymphangitis or lympha denopathy proximal to the ABSSS I 
 
Note that there is no requirement for a t least 1  marker of systemic inflammation  in 
participants ≥  70 years old or in participants with diabetes.  
Sex 
6. Females of child bearing  potential, <  [ADDRESS_765160] ( beta-human chorionic 
gonadotropin [ β-HCG ]) at baseline, a nd agree to use 2 highly effective methods  of birth 
control (eg, abstinence, oral contraceptive, intrauterine device, barrier contraception 
[condom]) to PTE. Females who are not of childbearing potential (have had a tubal 
ligation, hysterec tomy, or bilateral oophorectomy, or are ≥  2 years postmenopausal) or 
have a partner who has had a vasectomy do not need to use any contraception. Males 
must use a highly effective method of birth control if female partner(s) is of childbearing 
potential an d must not donate sperm from baseline through PTE. Contraception guidance 
is described further in Section  10.7. 
Informed Consent  
7. Capable of giving  signed informed consent as described in Section 10.1.4  which includes 
compliance with the requirements and restrictions listed in  the informed consent form  and 
in this protocol  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 30 
 
  5.2 Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Body mass index ≥30 kg/m2 (obese ) 
2. History or hypersensitivity or intolerability to any fluoroquinolone , rifamycin or 
glycopeptide  class 
3. ABSSSI  suspected or confirmed to be caused by [CONTACT_581887]   
4. Prior administration of systemic antibacterial therapy within 96 hours before 
randomization  
5. Pregnant or breastfeeding  
6. Evidence of significant hepatic, hematologic,  or immunologic  disease determined by [CONTACT_14504] : 
a. Acute hepatitis from any cause within the past year; participants with stable chronic 
hepatitis B and/or hepatitis C may be eligible provided they do not meet exclusion 
criteria  
b. Serum ALT, AST, or bilirubin greater than 2 times upper limit of n ormal  
c. Manifestations of  end-stage liver disease, such as ascites or hepatic encephalopathy  
d. Current or anticipated neutropenia defined as < 500 neutrophils/mm3 
e. Known infection with human immunodeficiency virus (HIV) and a cluster of 
differentiation 4 (CD4) count that is unknown or documented to be < 200 cells/mm3 
within the last year, or an Acquired Immune Deficiency Syndrome (AIDS) -defining 
illness  
f. The receipt of cancer chemotherapy, radiotherapy, or potent noncorticosteroid 
immunosuppressant drugs (eg, cyc losporine, azathioprine, tacrolimus, 
immune -modulating monoclonal antibody therapy, etc.) within the past 3 months, or 
the receipt of corticosteroids equivalent to or greater than 40 mg of prednisone/day or 
for more than 14 days in the prior 30 days  
7. QT int erval corrected with Fridericia’s formula (QTcF) >  450 msec based on the average 
of screening ECGs in triplicate; or history of QT prolongation, clinically significant 
hypokalemia, or other proarrhythmic conditions  
8. Has other contraindications to receiv e a systemic fluoroquinolone antibiotic, including 
confirmed or suspected peripheral neuropathy, tendon disorder, myasthenia gravis, 
cirrhosis, aortic aneurysm, or central nervous system disorder that may predispose the 
participant to seizures or lower the sei zure threshold  
9. History of Clostridium diff icile infection  
10. ABSSSI with any of the following char acteristics:  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 31 
 
  a. Suspected or confirmed  infection caused by  [CONTACT_152926] -negative or anaerobic organisms 
(eg, perineal wound infection, gluteal decubitus ulcer, wound infection associated 
with surgery on gastrointestinal tract or female genital tract, infection caused by a 
human or animal bite)  
b. Suspected or confirmed fungal, mycobacterial, parasitic, or viral pathogens  
c. Involving an ischemic ulcer due to peripheral vascular disease  
d. Involving a decubitus ulcer or perirectal abscess  
e. Involving a  diabetic foot ulcer  
f. Involving a burn  
g. Involving an underlying inflammatory skin disease that may obscure determination of 
response (eg, chronic dermatitis) where infla mmation may be promine nt for an 
extended period , even after successful bacterial eradication has been achieved  
h. Involving a bite other than an arthropod bite (ie, human or animal bite)  
i. Involving a rapi[INVESTIGATOR_115880], such as necrotizing fasciitis  
j. Involving gangrene of any etiology  
k. Complicated by [CONTACT_581888] y (eg, development of ecthyma gangrenosum in 
neutropenic subject)  
l. Anatomically associated with prosthetic materials (eg, central venous catheters, 
permanent cardiac pacemaker battery packs , or joint replacement prostheses), even if 
the device is removed  
m. Requiring amputation  
n. Requiring significant surgical intervention (ie, procedures that would not normally be 
performed at the bedside) that cannot be performed within [ADDRESS_765161] udy 
intervention treatment  (Inclusion Criterion 3) 
o. Minor cutaneous abscess or furuncle  or any other condition with an  estimated high 
cure rate after surgical incision alone or after aggressive local skin care  
p. Associated with infection at other anatomic sites or spaces, such as endocarditis or 
other endovascular infection, thrombophlebitis, osteomyelitis, or septic arthritis  
q. Anticipated need for a ntibacte rial therapy for longer than  14 days 
11. History or evidence of severe renal disease or has a calculated creatinine clearance of 
< 30 mL/min, according to the Cockcroft -Gault equation ( Section  10.2, Table  11) 
12. Presence of any other surgical or medical condition (including a clinically significant 
laboratory abnormality) as determined by [CONTACT_1755]/or the sponsor’s medical 
monitor, that could interfere with the participant’s ability to participate in the study, the 
administration of study intervention, and/or the interpretation  of study results.  
13. Anticipated need for concomitant use of medications from randomization to EOT : HIV 
protease inhibitors (eg, ritonavir -boosted or non -boosted saquinavir, a tazanavir, 
darunavir, fosamprenavir, or tipranavir ); praziquantel , halothane , and C lass IA and III 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 32 
 
  anti-arrhythmic s (eg, disopyramide, procainamide, quinidine, amiodarone, dofetilide, 
dronedarone, ibutilide , and sotalol ) (Table 20). 
Prior/ Concurrent Clinical Study Experience  
14. Previous enrollment in this study or previous treatment with TNP -2092  
15. Received an inves tigational medication within 30  days or 5 half -lives (whichever is 
longer) before the first dose of study intervention.  
5.3 Lifestyle Considerations  
After switching to  oral antibiotic treatment, food or drug restrictions  (Section  6.6.2 ) may be 
necessary, depending on the antibiotic chosen. The  investigator will inform the participants 
of any restrictions after reviewing  the prescribing information  for each antibiotic . 
5.4 Scree n Failures  
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomly assigned to study i ntervention . Individuals who do not meet 
the criteria for participation in this study (screen failu re) can be rescreened.  
A minimal set of screen failure information is required and will be collected to ensure 
transparent reporting of screen failure participants to meet the Consolidated Standar ds of 
Reporting Trials  publishing requirements and to respon d to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility 
criteria,  and any SAE . 
[ADDRESS_765162] part of 
this study, each participant will receive an IV infusion q12h  of study intervention for a 
minimum of 3 days (6 doses) . Intervention comprising IV or IV plus oral medications  switch  
(if applicable)  will be administered for a minimum of 7  days up to 14 days . After the IV 
infusion  part of the study is completed  and participants  meet switching criteria,  they will be 
switched  to a commercially -available , oral, open -label  antibiotic  selected by [CONTACT_093] . 
6.1 Study Interventions  Administered  
One-hundred twenty participants w ho meet study entry criteria  will be randomly assigned to 
treatment in 1 of 2 treatment arms in a  2:1 ratio as presented in Table  2. A sample size of 
80 participants who receive  TNP -2092  is deemed sufficient to provide an initial assessment 
of safety and PK data to inform the future development of TNP -2092 . 
The study intervention refers to supplied  IV TNP -2092 and IV vancomycin and the 
commercially available, open -label , oral  antibiotic . Infusions of stud y intervention will be 
administered  as follows:  
• TNP -2092 –300 mg IV q12h  infusion will be administered over 60 minut es (treatment 
arm A) for a mini mum of 3  days (6 doses)  and a maximum of 14 days   
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 33 
 
  • Vancomycin  - 1 g IV q12h  infusion will be administered over 60  minutes  (treatment 
arm B) for a minimu m of 3  days (6 doses)  and a maximum of [ADDRESS_765163] by 
[CONTACT_2300], lot number, manufacturer , storage conditions, and expi[INVESTIGATOR_5695]. Administration of the 
IV study intervention  is limite d to investigational use only. Refer to the Pharmacy Manual 
for additional information.  All supplies packed and labeled will be formally released in 
accordance with bot h Good Manufacturing Practice  and Good Clinical Practice  (GCP)  
guidelines.  
• Lyophilized TNP -2092 for IV administration will be provided in clear, glass vials (10  mL 
capacity) containing 100  mg TNP -2092. The vials should be kept frozen  (-20ºC) until 
reconstitution. One vial of lyophilized TNP -2092 will be reconstituted in 5  mL of sterile 
Water for I njection , USP, for a  final concentration of 20 mg/mL . Reconstituted 
TNP -2092 solution is injected into prepared IV bag at ambient temperature and diluted  in 
5% dextrose solution  as presented in Table  4. Once the drug product is reconstitute d, it 
will be stored for no longer than 4 hours at ambient temperature.  
• Commercially -available, l yophilized vancomycin for IV administration will be provided 
in clear, glass vials containing 1 g vancomycin. The vials should be kept at ambient 
temperature  until reconstitution.  One vial of lyophilized vancomycin will be reconstituted 
in 20 mL of Sterile Water for Injection, USP, for a final concentration of 50  mg/mL. 
Reconstituted vancomycin solution is injected into the prepared  IV bag , at ambient 
temperatu re, and diluted  with 5% dextrose solution  as presented in in Table  4. Once the 
drug product is reconstituted , it will be stored for no longer than [ADDRESS_765164] 3 days (ie, 6 doses ), after which participan ts may be 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 34 
 
  switched to the oral  antibiotic  only (Section  6.2). Participan ts will be hospi[INVESTIGATOR_581874] . 
Study intervention will be dispensed to the sites as summarized in Schedule of Activities 
(Section  1.3). Re turned study intervention must  not be reused  and must be disposed of 
according to instructions provided in the pharmacy manual . Upon completion of the IV 
infusion part of the study, the c ommercially -available, oral antibiotic treatment will be 
administered in an open -label manner after participants meet the switching criteria described 
in Section  6.2. The prescribing information provided by [CONTACT_581889].  
6.[ADDRESS_765165] 3 days of study intervention  (ie, 6  doses of  TNP -2092  or vancomycin), 
participan ts may be switched from the twice daily  IV study intervention  to 
commercially -available,  open -label , oral antibiotic  therapy , if all of  the following conditions 
are met:  
• In the previous 24  hours, the participan t has had 4  temperature measurements, each 
separated by [CONTACT_140992] y 6 hours, and all 4  measurements are ≤  37.6°C  / 99.7°F.  
• Peripheral WBC  count and immature neutrophils returning or have returned to normal 
range  according to the loc al laboratory reference range  
• No increase from baseline or the previous visit in ABSSSI lesion area compared to the 
screening visit  or a previous visit  
• No increase in severity of inflammatory findings at the primary site of infection 
(erythema, edema, indu ration)  from baseline or a previous visit ; in general, the severity of 
these findings should be mild  
• Unequivocal i mprovement in some or all clinical signs of  ABSSSI under study; if some 
signs have not improved, none should have worsened (ie, stability for that sign is 
observed).  
• Ability to maintain oral intake  
 
Participants in  any treatment arm may be switched to oral therapy, o nce the investigator’s 
assessment of  clinical response is improvement , as described in Section  8.4.1 . When the 
participant is switched to oral therapy, tr eatment will continue in an open -label manner with 
no attempt to blind the oral treatment . The IV antibiotic treatment  will remain blinded  until 
the database is unlocked . The oral antibiotic w ill be selected by [CONTACT_581890] w ill be conducted in an open -label manner . 
6.3 Preparation/Handling/Storage/Accountability  
6.3.[ADDRESS_765166] be stored in a locked, secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with th e labeled storage conditions ( -20ºC ) with access 
limited to the investigator and authorized site staff.  
3. The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).  
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Pharmacy Manual.  
 
6.3.[ADDRESS_765167] the type and dosage of commercially -available , antibiotic  used. 
The oral antibiotic choice will not be blinded.  
6.4 Measures to Minimize Bias: Randomization and Blinding  
Participants will be randomly assigned in a 2:1 ratio of the study intervention s 
(TNP -2092:  vancomycin) . Randomization will be stratified by [CONTACT_115968] 
(cellulitis/erysipelas, wound infection, or major cutaneous abscess) ; however, participants 
with major cutaneous abscess should not comprise > 30% of randomized  population . All 
participants will be centrally assigned to randomized study intervention with an Interactive 
Web Response System (IWRS). Bef ore the study is initiated, login information and 
directions for the IWRS will be provided to each site.  
Investiga tors will remain blinded to each participant’s assigned study intervention throughout 
the study. After informed consent has been obtained and study eligibility established, the 
study site’s pharmacist or designee will obtain the  randomization number and th e study 
intervention assign ment from the IWRS and the participa nt is considered randomized. To 
maintain the blind, the study pharmacist will be responsible for the reconstitution and 
dispens ation of all study intervention . The participant  or legally author ized representative 
will also  be instructed  to avoid discussing the IV treatment or packaging of the study 
intervention with the investigator.  
This is a double -blind study. Those blinded to study intervention assignment include the 
sponsor, investigator, study statistician, clinical study personn el participating in direct 
participa nt care  and those involved in all clinical evaluation s. Those unblinded to study 
intervention  assignment include the pharmacy personnel, the unblinded study monitor , and 
the bioanalytical laboratory. To minimize the potential for bias, treatment randomization 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 36 
 
  information will be kept confidential by [CONTACT_581891], blinded investigator site personnel, or th e blinded study monitor 
until the conclusion of the study. Procedures to ensure that the blind is maintained are 
detailed in the  Study Blinding  Manual . 
Unblinding Study Intervention  
If study intervention is determined not to be safe and/or not tolerated, t he study interven tion 
assignment for those participan ts with a significant safety concern may be unblinded. The 
investigator and medical monitor will review the participant’s data, discuss the findings, and 
jointly decide to unblind the treatment assignmen t, continue  or terminate enrollment in the 
study.  
The blind may also be broken in the case of a medi cal emergency that requires  the 
investigator  to know the identity of the study intervention to appropriately guide the 
participa nt’s medical management. Bef ore unblinding  the treatment , the investigator is 
strongly advised to discuss options with the medical monitor or appropriate sponsor study 
personnel. If the blind is broken for any reason and the investigator is unable to contact [CONTACT_581892] , the investigator must notify the sponsor as soon as 
possib le, without revealing the participan t’s study intervention assignment (unless i mportant 
to the safety of participan ts remaining in the study). All instances of treatment unblindi ng 
will be thoroughly investigated and documented by [CONTACT_115970].  
In the event of a quality a ssurance audit, the auditor will be allowed access to unblinded 
study intervention records at the sites to verify that randomization/dispensing has  been done 
accurately.  
6.[ADDRESS_765168] medical supervision of the 
investigator, and recorded on the electronic case report form ( eCRF ). Participants who are 
not hospi[INVESTIGATOR_581875] r eturn to the clinic or hospi[INVESTIGATOR_581876]. The following compliance information will be documented and reporte d in the 
eCRF : 
• The dates and times of administration of each IV study intervention.  
• For IV infusion, the time when infusion starts and when it ends  is recorded along with the 
total volume of solution administered (if infusion is halted or interrupted for any reason, 
the time of premature discontinuation and re -initiation of infusion  is recorded ). 
Participants managed as outpati ents who receive oral antibiotics will self -administer study 
intervention. At the EOT, unused study medication  and used/empty bottles  will be collected 
and used to dete rmine compliance to treatment. Compliance will be calculated on the number 
of doses of s tudy intervention administered, divided by [CONTACT_581893] m the eCRF . Deviations from the prescribed dosage regimen 
will be recorded on the eCRF.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 37 
 
  A further check of compliance will be t he determination  of blood concentrations of 
TNP -2092 during the analytical phase of the study  (Section  10.4). 
6.6 Concomitant Therapy  
6.6.1 Other Medication Therapy  
All prescription medications and over -the-counter medications, including herbal, nutritional, 
and dietary supplements (eg, any antacid, iron supplement, or multivitamin) administered 
within 2 weeks (14  days) before randomization and during the study  between Da y 1 and 
LTFU  will be documented in the eCRF. Any changes in prior or concomitant medic ations 
will also be recorded.  
In addition to the name [CONTACT_11889], the following information will be collected and 
documented:  
• Reason for use  
• Dates of administratio n including start and end dates  
• Dosage information including dose and frequency  
 
The medical m onitor should be contact[CONTACT_63193].  
6.6.[ADDRESS_765169] drug -drug interactions 
with rifamycin  or fluoroquinolones . The investigators will receive the prescribing 
information fo r rifam pin (2019 ) and moxifloxacin ( 2016 ). The investigator s should review 
this information about these agents as representative exampl es from  these drug classes . In 
addition, training sessions will be provided to the investigators regarding these drug classes.  
6.6.3 Adjunctive Therapy  
The following non -drug adjunctive therapi[INVESTIGATOR_86042]:  
a. Local bedside wound care as per hospi[INVESTIGATOR_23155]  
b. Lesion d ebridement at the bedside  
c. If required, surgical procedures to treat ABSSSI (eg, I&D) should be performed  
before the first dose of study intervention up to 24 hours  (Day 2)  after the first dose of 
study interven tion. After Day 2, if perform ed, any surgical intervention will be 
captured; however, subject evaluability in analysis populations may be affected . 
TNP -[ADDRESS_765170] udy 
Continuation of study intervention beyond the 14 -day treatment period is not permitted  
following the end of the  study because participants with  ABSSSI should be cured.  For 
participants who withdra w from treatment  because of lack of efficacy, all safety assessments 
from the EOT visit should be completed before rescue therapy with another antibiotic is 
initiated.  
7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1 Discontinuation of Stud y Intervention  
Participants who prematurely discontinue trea tment will remain in the study.  Before 
premature discontinuation, the study site personnel should notify t he medical monitor, time 
permitting . Efforts will be made by [CONTACT_581894]-specified assessme nts 
listed for the EOT visit  as appropriate, and to perform follow -up safety assessments  as 
specified at the PTE visit and L TFU visit as scheduled. Ongoing AEs should be following to 
resolution or to a satisfactory outcome, as determ ined by [CONTACT_093].  Participan ts who 
withdraw will not be replaced. See the S chedule of Activities  for data to be collected at the 
time of interven tion discontinuation and follow -up and for any further evaluations that need 
to be completed  (Section  1.3). 
7.2 Participant Discontinuation/Withdrawal from the Study  
Participants have the right to withdraw from the study without prejudice by  [CONTACT_581895]. All participants should be 
encouraged to complete all study assessments before withdrawal, as shown in the S chedule 
of Activities  (Section  1.3). Study assessments should be completed before any rescue therapy 
is initiated. After the study assessments are completed the participant will be permanently 
discontinued from the  study. If the participant withdraws consent for disclosure of future 
information, the sponsor may retain and continue to use any data collected before consent is 
withdrawn . If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the  investigator must document the request and destruction  
in the site study records.  
Data for all participants will be reviewed to ensure that the investigators are following the 
protocol -defined criteria for clinical resp onse and queries will be issued as needed to clarify 
any response that does not meet the protocol definition.  
TNP -[ADDRESS_765171] be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_581896]/or should continue in the 
study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_112631]’s 
medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
 
Discontinuation of specific s ites or of the study are handled as part of Section  10.1.[ADDRESS_765172] (IRB). Each i nvestigator will be responsible  
for enrolling only those participan ts who have met the protocol inclu sion and exclusion 
criteria.  
• Study procedures and their timing are summarized in Section  1.3. Protocol waivers or 
exemptions are not allowed.  
• Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant should  continue or discontinue 
study intervention.  
• Adherence to the study design requirements, incl uding those specified in the Schedule of 
Activities  (Section  1.3), is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the informed consent form ( ICF) may be utilized 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 40 
 
  for screening or baseline purposes provided the procedures met the protocol -specified 
criteria and were performed within t he time frame defined in the Schedule of Activities . 
• Blood samples will be collected from each participant over the duration of the study, and 
extra assessments will be collected as  required . The sponsor anticipates that the total 
amount of blood will not exceed [ADDRESS_765173] 
be documented and approved by [CONTACT_581897] s ite study files and will not constitute a protocol amendment. The IRB, IEC will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICF . 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 41 
 
  8.2 Safety Assessments  
Planned time points for all safety assessme nts are provided in the Schedule of Activities  
(Section  1.3). 
8.2.1 Physical Examinations  
Physical examinations , both complete and focused,  will be performed  as follows:  
• A complete physical examination comprises weight, height  (screening only) , general 
appe arance, head, ears, eyes, nose, throat, dentition, thyroid, chest (heart, lungs), 
abdomen, skin/soft tissues, neurological, extremities, back, neck , musculoskeletal, and 
lymph nodes.  
• A focused physical examination comprises  chest (heart, lungs), abdomen, s kin, 
neurological and musculoskeletal systems.  
Complete physical examinations will be performed at the screening,  EOIV, EOT, and PTE 
visits. Focused physical examinations will be performed on  Day 2, EA, and every subsequent 
day of IV treatment (minus EOIV) . 
 
8.2.2 Vital Signs  
Vital signs will be assessed  preferably by [CONTACT_581898]:  
• Temperature (oral ), pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed.  
• Blood pressure and pulse measurements will be assessed in the sitting position with a 
completely automated device. Manual techniques will be used only if an automated 
device is unavailable.  
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_765174]  
in a quiet setting without distractions (eg, television, cell phones).  
• Vital signs (taken before blood collection for labora tory and PK assessments ) will consist 
of 1 pulse and 3 blood pressure measurements ([ADDRESS_765175] 1  minute). The average of the [ADDRESS_765176] 1  minute, before collection of blood for laboratory and PK assessments, and within 
4 hours (± 30 minutes) of study intervention administration. These assessments will be 
performed at screening, EA, EOT, and PTE . 
8.2.4 Clinical Safety Laboratory Assessments  
Central laboratory safet y assessments for hematology, coagulation, serum chemistry, and 
urinalysis will be performed at each visit from screening through PTE  according to the 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 42 
 
  Schedule of Activities ( Table  3). Specifically, central laboratory assessments include β -HCG 
pregnancy test at baseline and EOT, and hematology, coagulation, serum chemistry , and 
urinalysis testing at each visit from screening through PTE. Given the duration of time 
required to ship, receive, and analyze the central laboratory tests, the central laboratory 
results will not be available to immediately affect participant manage ment in real -time. 
Therefore, local laboratory testing should be performed as needed according to  local 
standards of care to appropriately manage participants.  
Local laboratory test s are required to ensure eligibility at screening ( Section  5.1 and 
Section  5.2). Specifically, local laboratory testing for eligibility includes plasma WBC count 
and immature neutrophil percentage (potentially required to meet Inclusion Criterion 5); 
β-HCG pregnancy testing ( Inclusion Criteria 6); serum ALT, AST, total bilirubin, and 
absolute neutrophil count ( Exclusion Criterion 6); and serum creatinine for creatinine 
clearance calculation ( Exclusion Criterion 11). Any other local laboratory samples may be 
collected as part of site -specific routine management of participants per local standards of 
care, whether at baseline or postbase line.  
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study, including any value beyond PTE, should be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by [CONTACT_63200]. Additional details of clinical laboratory testing are presented 
in the Laboratory Manual .  
A complete list of tests to be performed is presented in Section  10.2 (Table  11).  
The investigator duties regarding laboratory test results are as follows:  
• The investigator must review the laboratory report, document this review, and record any 
clinicall y significant  chang es occurring during the study in the AE section of the eCRF. 
The laboratory reports must be filed with the source documents. Clinically significant 
abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged b y the investigator to be more severe than expected for the 
participant's condition.  
• All laboratory tests with values considered clinically significantly abnormal du ring 
participation in the study , including any value beyond PTE,  should be repeated until th e 
values return to normal or baseline or are no longer considered clinically significant by 
[CONTACT_10982].  
• If such values do not re turn to normal/baseline withi n a period judged reasonable by [CONTACT_1275], the etiology should be i dentified , and the sponsor notified.  
• All protocol -required laboratory assessments, as defined in Section 10.2, must be 
conducted in accordance with the laboratory manual and the Schedule of Activities  
(Section  1.3). 
• If values from laboratory assessments not specified in the prot ocol performed at the 
institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE), then the results 
must be recorded in the eCRF.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 43 
 
   
8.3 Adverse Events and Serious Adverse  Events  
The definitions of an AE  (Table  12), SAE  (Table  14), and  the types of events meeting the  
definition of AE (Table  13) are presented in Section  10.3. Adverse events will be reported by 
[CONTACT_581899]. The investigator and 
any qualified designees are responsible for detecting, documenting, and recording events that 
meet the definition of an AE or SAE  as presented in Table  15. They  remain responsible for 
following up AEs that are serious, considered related to the study intervention or study 
procedures, or that caused the participant to discontinue the study intervention or study.  
Thrombotic and infusion site AEs will be considered events of special interest and will be 
collected and documented separately from AEs  from the screening to EOIV  visits 
(Section  1.3). 
8.3.1 Period and Fr equency for Collecting AE and SAE Information  
All AEs and SAEs will  be collected from the time  the ICF is signed to the LTFU  visit, 
20 to 25 days after the EOT, at the time points specified in the Schedule of Activities 
(Section  1.3). Medical occurrences that begin before the start of study intervention but after 
obtaining informed consent will be recorded on the Medical History/Current Medical 
Conditions section of the eCRF and not within the AE section. All SAEs will be recorded 
and r eported to the sponsor or designee immediate ly within 24  hours  of awareness , as 
presented  in Table  19. The investigator will submit any updated SAE d ata to the sponsor 
within 24 hours of it being available.  
After the conclusion of the study (LTFU), investigators are  not obligated to actively seek AE 
or SAE information . However, the investigator must promptly notify the sponsor if the 
investigator learn s of any SAE, including a death, at any time after a participant has been 
discharged from the study, and he/she considers the event to be reasonably related to the 
study intervention or study participation.  
8.3.2 Method of Detecting AEs and SAEs  
The method of re cording, evaluating, and assessing the intensity and causality of AE s and 
SAE s and the procedures for completing and tra nsmitting SAE reports are present ed in 
Table  16 and Table  17, respectively.  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.  
8.3.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/co ntacts. All SAEs, AEs that lead to discontinuation, and AEs 
of special interest Section  10.3, will be followed until resolution, stabilization, th e event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). Further 
information on follow -up procedures i s given in  Section  10.3.3 . 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 44 
 
  8.3.4 Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities toward  the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
• The sponsor h as a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The sponsor will comply with country -specific regulatory requirements 
relating to s afety reporting to the regulatory autho rity, IRB  /Independent Ethics 
Committee  (IEC) , and investigators.  
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary.  
• An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (eg, summary or listing of SAEs) from the sponsor will 
review and then file it along with the Investigator’s Brochure and will notify the 
IRBs/IEC s, if appropriate according to local requirements.  
 
8.3.[ADDRESS_765177] will be performed at screening and at the EOT for all women of 
childbearing potential.  
• Details of all pregnancies in female participants and female partners of male participants 
will be collected after the start of study intervention until the outcome of the pregnancy is 
determined . 
• If a pregnancy is reported, the investigator should inform  the sponsor within 24  hours of 
learning of the pregnancy and should follow the procedures described in Section  10.7. 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs  and will be reported 
following the SAE reporting process  (Section  10.3.5 ). 
 
The risks of treatment with TNP -[ADDRESS_765178] not been fully evaluated. 
Therefore, females of chi ldbearing  potential,  < [ADDRESS_765179] (β -HCG) at 
baseline , and agree to use 2 highly effective methods  of birth control (eg, abstinence, oral 
contraceptive, intrauterine device, barrier contraception [ condom] ) to PTE. Females  who are 
not of childbearing potential (have had a tubal ligation, hysterectomy, or b ilateral 
oophorectomy, or are ≥  2 year s postmenopausal) or have a partner who has had a vasectomy 
do not need to use any contraception . Males  must use a highly effective method of birth 
control if female partner(s) is of childbearing potential and must not donate sperm from 
baseline through PTE . Contraception guidance is described further in Section  10.7. 
TNP -[ADDRESS_765180] be reported, regardless of 
the cause or relationship to study medication.  If a death occurs greater after the LTFU visit  
and is considere d possibly related to study intervention , the investigator should report the 
death and associated event on the SAE Report Form.  
8.3.7 Disease-Related Events and/or Disease -Related Outcomes Not Qualifying as 
AEs or SAEs  
Worsening of the primary ABSSSI for which the participant was enr olled is not considered 
an AE. All e vents that do not quality as an AE or SAE are presented in Table  12. 
8.[ADDRESS_765181] ion, if known (eg, trauma, arthropod bite, fungal 
dermatosis, surgery, spontaneous, etc.) should be recorded.  
When conducting a clinical examination of the primary ABSSSI site, the investigator will 
perform and record the following assessments:  
• Extent of t he infection (area in cm2) as measured with a ruler provided by [CONTACT_456]. 
The area of redness, edema, or induration will be measured from the longest length 
multiplied by [CONTACT_115946]. Instructions for primary ABSSSI 
measurements are  described in the Site Infection Assessment and Measurement Manual.  
• Local signs and symptoms of erythema (and any distant extension of erythema), 
swelling/edema, localized warmth, tenderness on palpation, drainage, fluctuance, and 
induration as described i n the Site Infection Assessment and Measurement Manual.  
 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 46 
 
  Programmatic Determination of Clinical Response  
Objective evaluation of clinical response as determined programmatically will be made at the 
EA visit 48 to 72 hours after the study intervention begins. The lesion size will be a 
component of the clinical response and instructions for measuring lesions ar e provided in the 
Site Infection Assessment and Measurement Manual. Participants will be considered as 
responders, nonresponders, or indeterminate as defined in Table  5. 
Table  5 Clinical Response Definitions – Programmatic Determination  
Timepoint 
Classification  Definition  
At Early Assessment (48 to 72 hours after IV Treatment Starts)  
Responder  Percent reduction in primary ABSSS I lesion size is ≥  20% compared with baseline  
Did not die of any cause up to the specified visit  
Nonresponder  Percent reduction in primary ABSSSI lesion size is <  20% compared with baseline  
Intercurrent antibacterial therapy administered for the treatment of the primary 
ABSSSI lesion that might have potential antibiotic activity directed toward the 
gram -positive pathogens implicated in the ABSSSI  
Did not die of any cause up to the specified visit  
Indeterminate  Study data are unavailable for evalu ation of efficacy for any reason (eg, missing data, 
lost to follow -up, did not attend the EA clinic appointment)  
ABSSSI = acute bacterial skin and skin structure infection; EA = early assessment; IV  = intravenous  
 
Investigator’s Assessment of Clinical Response  
The investigator’s assessment of clinical response at EOIV, EOT, and PTE visits will be 
classified as defined in Table  6. Investigat or assessed clinical failures at EOT will be carried 
forward as the clinical response at PTE.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 47 
 
  Table  6 Clinical Response Definitions – Investigator’s Assessment  
Timepoint  
 Classification  Definition  
At EOIV  
Improvement  The ABSSSI sufficiently improved such that further IV antibacterial therapy is not 
needed. These participants may have some residual clinical signs and symptoms 
related to ABSSSI requiring continued oral antibiotic stepdown therapy (provided the 
subject me ets oral switch criteria, Section  6.2) or ancillary (ie, non -antibiotic) 
treatment, eg, bandages on a healing wound, debridement of uninfected tissue.  
Failure  Investigator discontinued study intervention and indicated that the ABSSSI had 
responded inadequately such that alternative (rescue) nonstudy IV antibacterial therapy 
was needed  
The participant received antibacterial therapy for a different infection that may be 
effective for the ABSSSI under study  
The participant developed an AE that required discontinuation of stu dy intervention 
before completion of the planned IV regimen  
Unplanned major surgical intervention (ie, procedures that would not normally be 
performed at the bedside) for the ABSSSI under study  
Died of any cause up to the specified visit  
Indeterminate  Study data are unavailable for evaluation of efficacy for any reason (eg, missing data, 
lost to follow -up). 
EOT and PTE  
Success  The ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. 
These participants may have some residual changes related to infection requiring 
ancillary (ie, non -antibiotic) treatment, eg, bandages on a healing wound, debridement 
of uninfected tissue (ie, necrotic)  
Did not die of any cause up to the specified visit  
Failure  Investigator discontinued  study intervention and indicated that the ABSSSI had 
responded inadequately such that alternative (rescue) non -study antibacterial therapy 
was needed  
The subject received antibacterial therapy for a different infection that may be effective 
for the ABSSSI  under study  
The subject developed an AE that required discontinuation of study intervention before 
completion of the planned treatment regimen  
Unplanned major surgical intervention (ie, procedures that would not normally be 
performed at the bedside) for t he ABSSSI under study  
Died of any cause up to the specified visit  
Indeterminate  Study data are unavailable for evaluation of efficacy for any reason (eg, missing data, 
lost to follow -up). 
ABSSSI = acute bacterial skin and skin structure infection; EOIV = end of IV treatment; EOT = end of 
treatment; PTE = posttreatment evaluation  
8.4.[ADDRESS_765182] undergo microbiological 
assessments at screening, bacterial culture and Gram -stain, except  microbiological 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 48 
 
  assessments from  cellulitis  lesions are optional (eg, invasive tissue samples are encouraged 
but not required from cellulitis lesions) . Samples from local ABSSSI site specimens, and 
blood cultures from [ADDRESS_765183] pathogens responsible for ABSSSI is an important 
secondary outcome of the study ( Table  1). Similarly, participants with an infection  suspected 
or confirmed to be caused by  [CONTACT_152926]-negative bacteria (eg, Pseudomonas aeruginosa  in burn 
patients) , and a naerobic pathogens, mycobacteria,  or fungi should not be enrolled, and 
participants with ABSSSI suspected or confirmed to be caused by [CONTACT_152926] -positive bacteria will 
be analyzed in the microbiological populations. If an enrolled participant is subsequently 
found to have a confirmed infection  with gram -negative or anaerobic organisms, they may 
remain in the study but may be switched to the appropriate antibiotic.  
The ABSSSI site specimens are collected at screening, when clinically indicated, or if the 
participant is deemed a clinical failure.  The following types of specimens are considered 
acceptable, in order of preference:  
• Biopsy of involved cutaneous or subcutaneous tissue, preferably from the advancing 
margin of the lesion  
• Debrided tissue  
• Tissue scrapi[INVESTIGATOR_007] (with curette or scalpel)  
• Needle as pi[INVESTIGATOR_494179], nonpurulent cutaneous or subcutaneous tissue  
• Pus or infect ed tissue collected during an I& D procedure  
• Pus aspi[INVESTIGATOR_38105] a syringe  
• Deep swab of purulent material (only if collected from infected tissue that has been 
incised or is draini ng) 
 
Deep swabs of infected areas taken during significant surgical interventions are acceptable 
specimens. Superficial swabs of infected areas are not acceptable, due to the high probability 
that such specimens could be contaminated with clinically insign ificant, and potentially 
misleading isolates.  
Two sets of blood cultures comprising [ADDRESS_765184] 
consider m odifying the antibiotic treatment administered to the participant and discuss the 
case with the medical monitor.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 49 
 
  All blood cultures and ABSSSI site specimens will be processed for Gram -stain and culture 
at the local laboratory. Laboratory reports on Gram -stain should include a semiquantitative 
description of the number of polymorphonuclear leukocytes per low power field (ie, 100×) 
and a description of bacterial morphologies. All bacterial isolates that are identified from an 
ABSSSI site specimen or blood cu lture at the local facilities collaborating laboratory will be 
sent to a designated central laboratory for confirmation of species identification and 
antimicrobial susceptibility testing. All microbiological specimen and processing detail s 
methods are desc ribed in the laboratory m anual.  
Antimicrobial susceptibility testing should be performed at the local laboratory according to 
local standards of ca re; all clinically significant g ram-positive pathogens should be tested 
locally for rifamycin , fluoroquinolon e, and vancomycin susceptibility, as appropriate. 
Susceptibility testing for TNP -[ADDRESS_765185] all g ram-positive isolates for rifamycin , 
fluoroquinolone, and vancomycin susceptibilities. The local laboratory should retain all 
isolates until confirmation of a viable organism is received from the central laboratory. Back -
up cultures will be requested when the central laboratory do es not receive a viable culture  or 
recovers an organism different from the one recorded by [CONTACT_97933]. All necessary 
procedures for antimicrobial susceptibility testing are described in the laboratory m anual.  
Per-Pathogen Microbiological Response  
A microbiological outcome at the  PTE visit is  determined  for each pathogen isolated from 
the ABSSSI site or blood at screening from the categories defined in Table  7. Favorable 
microbiological outcomes include eradication or presumed eradication. Unfavorable 
microbiological outcomes include persistence or presumed persistence.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 50 
 
  Table  7 Microbiologic Outcome Categories  
Outcome 
Category  Definition  
PTE  
Eradication  An adequate source specimen demonstrates absence of the original screening 
pathogens  
Presumed 
Eradication  An adequate source specimen was not available to culture and the participant was 
assessed as a clinical success by [CONTACT_581900] t o culture and the participant was 
assesse d as a clinical failure by [CONTACT_941] i nvestigator at PTE  
Indeterminate  An adequate source specimen was not available to culture and the participant’s clinical 
response was assessed as indeterminate  
PTE = posttreatment evaluation  
 
Per-Participant Microbiological Response  
An overall microbiological response at the PTE visit w ill be determined in the micro-ITT and 
ME population  for each participant based on individual outcomes for each  baseline  pathogen. 
For a parti cipant to have a favorable per -participant microbiological response, the  outco me 
for each  baseline  pathogen must be favorable (eradicated or presumed eradicated, as d efined 
in Table  7). For a participant t o have an unfavorable per -participant microbiological 
response, the outcome for  each baseline  pathogen must be  unfavorable (persistence, 
presumed persistence, as defined in Table  7). If the same pathogen is is olated from multiple 
sites (eg , blood and ABSSSI si te culture), the worst response will be used to determine the 
per-participant microbiological response.  
Emergent Infections  
ABSSSI caused by [CONTACT_581901] d in Table  8. 
Table  8 Emergent Infections  
Category  Definition  
End of Intravenous Treatment  
Superinfection  Isolation of a new pathogen other than the original screening pathogen from the 
primary ABSSSI site and from an appropriate ABSSSI specimen which is 
accompanied by [CONTACT_581902] t o and including EOT  
New Infection  Isolation of a new pathogen other than the original screening pathogen from the 
primary ABSSSI site and from an appropriate ABSSSI specimen which is 
accompanied by [CONTACT_581903] = acute bacterial skin and skin structure infection; EOT = end of treatment  
TNP -[ADDRESS_765186] multiple -dose/day was 600 mg for 14  days in the 
CBR -2092 -002 Clinical Study.  
An overdose is defined as deliberate or accide ntal admi nistration of TNP -2092  at a dose 
greater than twice the daily  dose assigned to that participant according to the protocol. In the 
event of a suspected overdose, the  investigator  should  take the following steps : 
1. Contact [CONTACT_581904] m onitor immediately.  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until  study 
intervention  can no longer be detected systemically (at least 30 days).  
3. Obtain a plasma sample for PK analysis within [ADDRESS_765187] dose of 
study in tervention if requested by [CONTACT_44686] m onitor (determined on a case -by-case 
basis).  
4. Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF.  
 
Decisions regarding dose interruptions or modificati ons will be made by [CONTACT_581905]’s  medical m onitor based on the clinical evaluation of the 
participant.  
In case of overdose of vancomycin or commercially -available, open -label, oral antibiotic, t he 
prescribing information ( 2018 ) should be consulted . 
8.6 Pharmacokinetics  
Pharmacokinetic samples will be obt ained from whole blood on Day  1 and at EOIV visits  
according to Table  21. Primary PK parameters will be calculated from concentration versus 
time data with noncompa rtmental techniques ( Cmax, tmax, AUC  versus time f rom tim e 0 to 
12 hours [A UC 0-12], and CL [after last dose]) . 
All participants from each treatment arm will  have  whole blood samples collected but only 
samples collected from participants in t reatment arm A  (TNP -2092 arm)  will be analyzed  
(Section  10.5). Some degree of infer ence may be possible to the influence of baseline 
participan t characteristics (eg, age, gender,  weight, body mass index , race) on the clearance 
of the drug.  
The bioanalytical laboratory will measure pl asma concentrations of TNP -2092  according to  
validated bioanalytical methods. Selected PK samples may be used in the identification of 
TNP -2092 metabo lites. Specific instructions for the collection of plasma and urine drug 
concentration specimens will be described in the Laboratory M anual and should be reviewed 
before collection.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 52 
 
  When multiple assessments are scheduled at any given timepoint, clinical a ssess ments should 
precede all blood collection , including ECGs.  
The actual date and time (24 -hour clock time) of each sample will be recorded. 
Approximately 5 mL/sample  will be collec ted for measurement of TNP -2092. Drug 
concentration information that woul d unblind the study will not be reported to investigative 
sites or blinded personnel unt il after the study treatment has been unblinded .  
The PK population is defined in Section  9.8. Additional details regarding the collection and 
analysis of PK samples are described in the PK Analysis Plan.  
8.7 Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study.  
8.8 Genetics  
Genetics are not evaluated in this study.  
8.9 Biomarkers  
Biomarkers are not evaluated in this study.  
8.10 Health Economics /Medical Resource Utilization and Health Economics  
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study . 
9 STATISTICAL CONSIDERATIONS  
All data will be summarized separately  by [CONTACT_62240]  (TNP -2092  300 mg q12h or 
vancomycin  1 g q12h ). Descriptive statistics (number, mean, standard deviation, median, 
minimum, and maximum) will be presented for continuo us variables for each study 
intervention . Frequency distributions (counts and percentages) will be presented for 
categorical variables. Listings will be provided for individual participa nt study data.  
A comprehensive  Statistical Analysis Plan (SAP)  will be prepared and finalized before the 
database is locked.  
9.[ADDRESS_765188] ical analysis. If the responder rate in the 
TNP -2092 arm is 0.8 at  EA ( 48 to 72 hours after start of study intervention ) according to the  
programmatic clinical response, this results in a 9 5% CI of (0. 7, 0.88) for the responder rate  
in the TNP -2092 ar m at the  EA visit (Clopper and Pearson, 1934 ). A sample size of 
80 participants who receive TNP -2092  is deemed sufficient to provide an initial assessment 
of safety and PK data to inform the future development of TNP -2092.  
9.3 Populations for Analyses  
The analysis populations are defined as presented in  Table  9 and Figure  3.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 53 
 
  Inclusion in the ITT, safety, and PK populations will be determined programmatically from 
eCRF data. Inclusion in the mITT population will be determined by [CONTACT_7195]. The 
medical monitor will decide whether each isolate is considered a pathogen. All manual 
reviews and determinations of population inclusion/exclusion requirements will be done 
before the study is unblinded.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 54 
 
  Table  9 Populations for Analysis  
Population  Description  
Intent -to-Treat (ITT)  All randomized participan ts will be included, regardless of whether study 
intervention is administered.  
Safety  All randomized participan ts who receive any amount of study intervention 
will constitu te the safety population. Participant s in the safety population 
will be analyzed according to study intervention received.  
Modified ITT (mITT)  All randomized participants in the ITT population excluding those 
participants who have gram -negative pathogens only.  
Microbio logic  ITT 
(micro -ITT)  All randomized participan ts in the mITT population with culture evidence 
of a baseline g ram-positive ABSSSI  pathogen s (exclude sole 
gram -negative and culture -negative participants)  
Clinically Evaluable  (CE)  All participants i n the ITT population who meet the minimal clinical 
disease criteria for ABSSSI; do not have any major protocol deviations, 
receive at least 80% of the expected doses of study intervention; do not 
receive any potentially -effective systemic antibacterial the rapi[INVESTIGATOR_581877] -specified study intervention ( except in cases of treatment failure).  
Included in the CE -EOIV population, if the following conditions are met:  
• Have an investigator's assessment of clinical response at EOIV 
(ie, neither response ca n be indeterminate)  
• Have an EOIV visit  (+ 1 day)  
• Included in the CE -EOT population, if the following conditions are 
met: 
• Have an investigator's assessment of clinical response at EOT 
(ie, neither response can be indeterminate)  
• Have an EOT visit  (+ 1 day)  
• Included in the CE -PTE population, if the following conditions are 
met: 
• Have an investigator's assessment of clinical response at PTE 
(ie, neither response can be indeterminate)  unless the participant was 
defined as a clinical failure based on the  assessment at EOT  
• Have a PTE visit  7 to 14 days after EOT, unless the participant was 
defined as a clinical failure based on the assessment at EOT  
Pharmacokinetic (PK)  All participants who receiv e at le ast [ADDRESS_765189] a 
sufficient number of  plasma samples for TNP -2092 PK analysis.  
Microbiologically Evaluable at 
PTE (ME -PTE)  All participants in th e micro -ITT population who belong to the CE -PTE 
population.  
ABSSSI = acute bacterial skin and skin structure infection; CE = clinically evaluable; EOIV = end of IV; 
EOT = end of treatment; ITT = intent -to-treat; mITT = modified ITT; micro -ITT = microbiological ITT; PTE 
= posttreatment evaluation  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 55 
 
  Figure  3 Overview of Analysis Populations  
 
ABSSSI = acute bacterial skin and skin structure infection; CE = clinically evaluable; EOIV = end of IV; EOT 
= end of therapy; ITT  = intent -to-treat; IV = intravenous; ME = microbiologically evaluable; mITT  = modified 
intent -to-treat; micro -ITT = microbiol ogical intent -to-treat; PK = pharmacokinetic; PTE  = posttreatment 
evaluation ; SAP  = statistical analysis plan  
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ITT Population  
All randomized participan ts 
Safety Population  
Participants  who receive 
any amount of study 
intervention  mITT Population  
Excludes participants with  only 
gram -negative pathogens  
CE-EOIV/ CE-EOT Population  
Participan ts with an EOIV or EOT 
visit and an Investigator’s assessment 
of clinical response  at EOIV or  EOT.  
ME-PTE  Population  
Micro -ITT population who also are in 
the CE -PTE population  CE-PTE  Population  
Participan ts with a PTE visit and an  
Investigator’s assessment of clinical 
response  completed at PTE  CE Population  
• Minimal ABSSSI disease criteria  
• Receive  ≥ 80% of study intervention ,  
• No concomitant systemic antibacterial 
therapy between Day  1 and assessment 
timepoint (except in cases of treatment 
failure)  
•  No major protocol violations  
PK Population  
Participants with at least 1 
dose of TNP -2092 and 
sufficient PK samples for 
analysis  Micro -ITT Population  
Participants with culture evidence 
of baseline gram -positive 
ABS SSI pathogen s 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 56 
 
  9.4 Analysis of Study Populations and Participan t Characteristics  
Enrollment, study interventions administered, premature discontinuations from study 
interventions, withdrawals from the study, and protocol deviations will be summarized by 
[CONTACT_2939] . A protocol deviation is defined as any variation from the prot ocol 
(eg, enrollment of a participan t who did not meet all inclusion and exclusion criteria, failure 
to perform the assessments and procedures within the required time frame).  
Demographics (age, race, sex), description of the baseline ABSSSI type, medical histor y, and 
baseline clinical signs and symptoms of ABSSSI will be summarized by [CONTACT_2939] . 
Baseline pathogens identified at the primary ABSSSI site will also be summ arized by 
[CONTACT_2939] . 
The number and percent age of participan ts in each population and r easons for exclusion from 
populations will be listed a nd summarized by [CONTACT_2939] . 
The SAP  will be developed and finalized before  the database is locked and will describe the 
participant populations to be included in the analyses, and procedures for acc ounting for 
missing, unused, and spurious data.  
9.5 Study Intervention Exposure  
By [CONTACT_581906], the number of 
IV doses  of antibiotic , and the number of commercially -available oral antibiotic doses. 
Compliance to study intervention  will be calculated based on  the total number of doses taken, 
divided by [CONTACT_581907].  A further check of compliance will be the 
determination of blood concentratio ns of TNP -2092  during the analytical phase of the study 
(Section  10.5). 
9.6 Safety Analyses  
Safety and tolerability of TNP -2092  IV, 300 mg  q12h,  will be assessed for a minimum of 
3 days (6 doses) and a maximum of 14 days to treat ABSSSI is the primary endpoint and the 
primary  objective of this P hase 2 study. Safety will be assessed by  [CONTACT_2695], physical 
examinations, vital signs, laboratory evaluations (hematology, chemistry, coagulation, 
urinalysis), and ECG parameters. For each safety par ameter, the last assessment  before the 
first administration of study intervention will be used as the baseline for all analyses.  
The incidence of treatment -emergent AEs  (defined in Table  12) will be presented by [CONTACT_581908] 
(MedDRA®); by [CONTACT_9313], preferred term , and relationship to  study intervention ; 
and by [CONTACT_9313], preferre d term , and severity. In additi on, the incidence of SAEs 
and treatment -emergent AEs leading to discontinuation of stu dy intervention  will be 
presented by [CONTACT_9313], preferred term , and relationship to study intervention . If the 
incidence of SAEs a nd treatment -emergent AEs leading to discontinuation of study 
intervention  is low, only a listing will be provided.  
Descriptive statistics of vital signs at each timepoint measured, as well as the change from 
baseline and potentially clinically significant  changes, will  be presented by [CONTACT_2939] . 
Potentially clinically significant ch anges will be defined in the SAP . Descriptive statistics f or 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 57 
 
  ECGs will also be presented for each timepoint measured  by [CONTACT_2939] . Abnormal 
physical examination data wil l also be summarized. Descriptive statistics for clinical 
laboratory tests and for the change from baseline will be presented by  [CONTACT_581909] . 
9.7 Efficacy Analyses  – Secondary Endpoints  
All secondary efficacy endpoints will be summarized by [CONTACT_581910]  10. 
9.7.1 Clinical Outcomes  
Programmatic clinica l response will be assessed at EA  in the ITT, mITT , and micro -ITT 
populations. The  number and percentage of participan ts with each outcome wi ll be 
summa rized by [CONTACT_2939] . Confidence intervals (95%)  will be provided for the responder 
rates at EA for each treatment arm . The difference between the responder/clinical response 
rates in the TNP -2092 treatment arm and  the vancomycin treatment arm  will be ca lculated 
and 95% CI for the difference between rates will be calculated  (Miettinen and Nurminen, 
1985 ). 
The i nvestigator’s assessm ent of clinical response at EOIV , EOT, and PTE  will be 
summarized for the  mITT, micro -ITT, CE-EOIV, CE -EOT, and CE -PTE populations, 
respectively . Success rates will be calculated for each analysis and differences in  success 
rates between the TNP -2092  and vancomycin treatment arm s will be calculated, a long with 
corres ponding 95% CI  will be presented according to the same methods used for the 
programmatic response . The  number and percentage of participan ts with sustained clinical 
response and clinical relapse will also be summarized at LTFU in the micro -ITT and CE -ME 
populations.  
Table  10 Efficacy Evaluations by [CONTACT_581911] -
ITT CE-
EOIV  CE-
EOT  CE-
PTE  ME-
PTE  
Secondary:  
Programmatic clinical response at EA   
√  
√  
√  
  
  
  
 
Per participant microbiological response 
at PTE    √    √ 
Microbiological response per baseline 
pathogen at PTE    √    √ 
Investigator’s assessment of clinical 
response at EOIV   √ √ √    
Investigator’s assessment of clinical 
response at EOT   √ √  √   
Investigator’s assessment of clinical 
response at PTE   √ √   √  
Investigator’s assessment of sustained 
clinical response at LTFU   √ √     
CE = clinically evaluable; EA = early assessment; EOIV = end of IV treatment; EOT = end of treatment; IV 
= intravenous; mITT = modified intent -to-treat; ME = microbiologically evaluable; 
micro --ITT = microbiological intent -to-treat; PTE = posttreatment evaluation  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 58 
 
  9.7.2 Microbiological Outcomes  
The number and percentage of participants with favorable microbiological responses will be 
summarized at PTE in the m icro-ITT and ME -PTE population s. Responses include 
eradication, presumed eradication, persistence, presumed persistence, and indeterminate 
(Table  7). Of these responses, eradication and presumed eradication will be regarded as a 
favorable outcome. Persistence and presumed persistence will be regarded as an unfavora ble 
outcome. If a participan t has >  [ADDRESS_765190] overall favorable response.  
The number and percentage of participan ts with a favorable outcome (eradication, presumed 
eradiation) will also be summarized for each baseline pathogen by  [CONTACT_581912]-ITT and ME -PTE population s. 
Emergent infections (eg , superinfection, new infection) will not be considered in the 
microbiological response and will be listed separately ( Table  8). 
9.8 Pharmacokinetic Analyses  
Characterization of the  PK of TNP -2092 for a minimum o f 3 days (6 doses)  and a max imum 
of 14  days to treat ABSSSI is an important secondary objective for this study. Plas ma 
samples from participants in t he PK population ( Section  10.5) will be an alyzed for TNP -2092 
concentrations with a validated bioanalytical method. Key basic PK par ameters will be 
assessed on Day  1 and at EOIV visits. Only  PK samples collected from participants 
randomized  to TNP -2092 (treatment a rm A) will be analyzed. Further d etails of the PK 
sample collection and analyses are provided the Statistical  Analysis Plan and Laboratory 
Manual . 
9.[ADDRESS_765191] all data at specified times. For secondary effica cy 
measure s, the outcome will be classified as indeterminate if  the data are unavailable for 
evaluation for any reason . A detailed desc ription of the handling of drop outs and missing, 
unused, and spurious data will be provided in the SAP . 
9.10 Interim Analyses  
No interim analysis or data monitoring committee is planned for this study.  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1 Regulatory, Ethical, and Study Oversight Considerations  
10.1.1  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the following:  
◦ Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences CIOMS  International E thical Guidelines  
◦ Applica ble ICH GCP  Guidelines  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 59 
 
  ◦ Applicable laws and regulations  
• The protocol, protocol amendm ents, ICF, IB , and other relevant documents (eg, 
advertisements) must be submitted to an IRB/IEC by [CONTACT_581913] t he IRB/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants.  
• The inves tigator will be responsible for the following:  
◦ Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
◦ Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
◦ Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studi es (if applicable), and all other applicable local 
regulations  
 
10.1.2  Financial Information  
[IP_ADDRESS]  Investigators and Subinvestigator Disclosure  
Investigators and sub investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators 
are responsible for providing information  on financial interests during  the study and f or 
1 year after completion of the study.  
[IP_ADDRESS]  Finance and Insurance  
The financing and insurance for this study are outlined in the Clinical Trial Agreement.  
10.1.3  Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_456]. Any participant record s 
or datasets that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_10999]. The level of disclosure must 
also be explained to the participant.  
• The participant must be informed that his/her medi cal records may be examined by 
[CONTACT_581914] a ssuran ce auditors or other authorized personnel appointed by [CONTACT_103], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 60 
 
  10.1.4  Informed Consent Process  
This study will be conducted in compliance with ICH E6 GCP: Consolidated Guidelines 
pertaining to informed consent. Participants will provide written consent to participate in the 
study at the first visit, before initiation of any study -related procedure after being informed of 
the purpose of the study as follows:  
• The investigator or his/ her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding 
the study.  
• Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 
[ADDRESS_765192] (HIPAA) requirements, where applicable, and the IRB/IEC or study 
site. 
• The med ical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
• In case of modifications, participants must reconsent to the most current version of the 
ICF during their participation in the study.  
• A copy of the ICF must be provided to the participant or the participant’s legally 
authorized representative. If applicable, it will be provided in certified translation for 
non-English speaking participants.  
Signed consent forms must remain in the participant’s study file and be available for 
verification by [CONTACT_581915] a competent regulatory agency at any  time. 
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research. The investigator or authorized designee will 
explain to each participant the objectives of the exploratory research. Par ticipants will be told 
that they are free to refuse to participate and may withdraw their consent at any time and for 
any reason during the storage period. A separate signature [CONTACT_22862] a 
participant's agreement to allow any remaining s pecimens to be used for exploratory 
research. Participants who decline to participate in this optional research will not provide this 
separate signature.  
10.1.[ADDRESS_765193] operating procedures from InClin will be followed to ensure that the study 
is conducted , data are generated, documente d (recorded), and reported in compliance with 
the protocol, GCP, and the applicable regulatory requirements. Quality control will be 
applied to each stage of data handling. Regular monitoring, as defined in ICH GCP, 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 61 
 
  Section  1.8, “The act of overseeing the progress of a clinical trial, and of ensuring that it is 
conducted, recorded, and reported in accordance with the protocol, standard operating 
procedures, GCP, and the applicable regulatory requirement(s)”, will be conducted 
throughout the conduct of the s tudy.  
Each investigator must adhere to the protocol as described in Section  8.1. The investigator 
will allow representatives of the sponsor or regulatory authorities to inspect facilities and 
records relevant to this study.  
The sponsor or sponsor representative will conduct site visits to inspect study data, 
participants’ medical records, and eCRFs in accordance with current ICH E6 GCP guideline,  
and regulations and guidelines, as applicable. Data for all participants will be reviewed to 
ensure the investigators are following the protocol -criteria for clinical response and queries 
will be issued as needed to clarify any response that does not meet  the protocol definition. 
The sponsor or sponsor representative will also be able to review query status remotely, 
which may warrant additional communication with the investigator and the study site’s 
personnel. The investigator will make available to the sponsor, or sponsor representative, 
source documents, s igned ICFs, and all other study -related documents. An unblinded monitor 
will be utilized for monitoring ongoing drug accountability and adherence to blinding 
procedures.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 62 
 
  The purpose of monitoring is to  verify that:  
• Rights and w ell-being of the human participant s are protected  
• The reported study data are accurate, complete, and verifiable from source documents  
• The conduct of the study is compliant  with the currently ap proved protocol , with GCP, 
and with the applicable regulatory requirements  
• Monitoring is an integral role in the quality control of a clinical trial and is designed to 
verify the quality of the study  
To fulfill the quality assurance requirements of GCP, audits wi ll be conducted to assess and 
ensure the reliability and in tegrity of the  QC systems for the study and recognized standards.  
The purpose of an audit is to:  
• Ensure participan t safety  
• Ensure compliance to study protocol procedures, regulatory requirements, and standard 
operati ng procedures  
• Ensure data quality  
Further instructions for the site and sponsor are presented below:  
• All participant data relating to the study  will be recorded on an e CRF unless transmitted 
to the sponsor or designee electronically (eg, laboratory data). The investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_56857].  
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF . 
• Monitoring details describing strategy (eg, risk -based initiatives in operations and quality 
such as Risk Management and Mitigation  Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncom pliance issues and monitoring tech niques (central, remote, or on -site monitoring) 
are provided in the Monitoring Plan . 
• The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
• The sponsor assumes accountability for actions delegated to other individuals (eg, 
Contract Research Organizations).  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], complete, an d verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulat ory requirements.  
• Records and documents, including signed ICFs, laboratory test results, and medication 
inventory records pertaining to the conduct of this study must be retained by [CONTACT_581916] -[ADDRESS_765194]  unless local regulations or institutional 
policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without w ritten notification to the sponsor.  
10.1.7  Electronic Case Repo rt Forms and Data Capture System  
This study will be performed with an eCRF. All eCRF data are to be completed by 
[CONTACT_16795]. All data entry, modification, or deletion will be recorded 
automatically in the electronic audit trail. All electronic data entered by [CONTACT_779] (including 
the electronic audit trail) will be maintained or made available at the site in compliance with 
[ADDRESS_765195] participant is treated with study intervention at an investigational site, the 
sponsor or sponsor representative will meet with the investigator and the study site’s 
personnel to train them to record the data on the eCRFs from an electronic data  capture 
system. The investigator or designee will be responsible for reviewing eCRFs, resolving data 
queries generated by [CONTACT_581917], providing missing or corrected data, and 
approving all changes performed on the participant data. This ap proval method will include 
applying an electronic signature, a uniquely assigned user name, and a password that together 
will represent a traditional handwritten signature. This electronic signature [CONTACT_581924] 21 CFR Part 11. The spon sor will retain the original eCRF data and audit trail. 
An electronic or certified paper copy of all completed eCRF data, including query resolution 
correspon dence, will be provided to the i nvestigator at the end of the study.  
Queries may be issued electro nically to the clinical study site and will be answered 
electronically by [CONTACT_581918]’s personnel. The identifying information (assigned user 
name, date, and time) for both the originator of the query and the originator of the data 
change (if applicabl e) will be collected.  
10.1.[ADDRESS_765196]. Source documents provide 
evidence for the existence of the participant and substantiate the integrity of the data 
collected and are filed a t the investigator’s site. Data reported or entered in the eCRF that are 
transcribed from source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may need to request previous medical 
records or  transfer records, depending on the study. Also, current medical records must be 
available. The definition of what constitutes source data can be found in the Monitoring Plan.  
The investigator agrees that by [CONTACT_5657]/her participation the results of this study may be used for 
submission to national or international registration. The sponsor or sponsor’s representative 
has ethical, legal, and scientific obligations to monitor this study in a detailed and orderly 
manner in accordance with established research prin ciples and applicable local regulations. 
As part of a concerted effort to fulfill these obligations, the sponsor’s monitors or 
TNP -[ADDRESS_765197] be available for inspection by [CONTACT_188553], 
by [CONTACT_581919]. At a participant’s request, medical information 
may be given to his or her personal physician or other appropriate medical personnel 
responsible for his or her welfare. Medical information obtained from participants during the 
study is confidential and disclosure to third parties other than those noted abov e is prohibited.  
10.1.9  Study and Site Closure  
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. The investigator may initiate study  
site closure at any time, p rovided there is reasonable cause and sufficient notice is given in 
advance of the intended termination. Reasons for the early closure of a study site by [CONTACT_581920]:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of further study intervention development  
• Fabrication or alteration of data  
Study sites will be closed upon study completion. A study site is considered closed when all 
required documents and study supplies have been collected and a study  site closure visit has 
been performed.  The sponsor requires  the availability of the following data and materials 
before a study can be considered complete or terminated:  
• Laboratory findings, clinical data, and all special test results from screening  through 
LTFU for participant s enrolled.  
• eCRFs (including queries)  properly completed by [CONTACT_27957].  
• Complete drug accountability records (drug inventory log and an inventory of returned or 
destroyed clinical material).  
• Copi[INVESTIGATOR_581878], if appropriate.  
• A summary of the trial conduct and ethical considerations of the study prepared by [CONTACT_192682] r (an IRB  summ ary letter is acceptable) . 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 65 
 
  This study will be conducted in compliance with the ICH of Technical Require ments for 
Registration of Pharmaceuticals for Human Use E6 GCP: Consolidated Guidelines, the 
ethical principles of the Declaration of Helsinki, FDA GCP guidelines, and any additional 
IRB-required procedures.  
10.1.[ADDRESS_765198] 
editorial and ethical practice, the sponsor will generally support publication of multicenter 
studies only in their entirety and not as individual site data. In this case, a coordinating 
investigator [INVESTIGATOR_581879].  Authorship will be determ ined by 
[CONTACT_445436] -line with International Committee of Medical Journal Editors 
authorship requirements.  
10.1.12  Data Management and Monitoring  
Training sessions, regular monitoring of the investigative site by [CONTACT_19981] r-designated 
personnel, instruction manuals, data verification, crosschecking, and data audits will be 
performed to ensure quality of all study data.  
It will be the responsibility of the investigator to ensure that essential documents are 
available in the investigator’s files or at the institutional site. All documents may be subject 
to, and should be available for, monitoring by [CONTACT_581921].  
TNP -[ADDRESS_765199] of Prohibited  Concomitant  Medications  
Drug Class  Subclass  Generic Name  
[CONTACT_74939]-arrhythmics  IA Disopyramide  
Procainamide  
Quinidine  
III Amiodarone  
Dofetilide  
Dronedarone  
Ibutilide  
Sotalol  
Antimicrobials  Antiparasitics  Praziquantel  
Anesthetics   Halothane  
HIV-protease inhibitors   Ritonavir -boosted saquinavir  
Saquinavir  
Atazanavir  
Darunavir  
Fosamprenavir  
Tipranavir  
HIV = human immunodeficiency virus  
Note: Medication use is prohibited by [CONTACT_581922] ( Section 5.2). 
Source: Prescribing information for rifampin (2019) and moxifloxacin (2016 ). 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 74 
 
  10.5 Pharmacokinetic Sample Schedule for Pharmacokinetic Assessments  
Primary PK parameters will be calculated from concentration versus time  data wit h 
noncompartmental techniques. These parameters  include Cmax, tmax, AUC 0-12, and CL (after 
last dose) . 
All participants from each treatment arm  will h ave whole blood samples collected on Day  1 
and at the EOIV visit . Only PK samples collected from participants in treatment arm A 
(TNP -2092 arm) will be analyzed and is presented in Table  21. Bioanalytical testing will be 
performed by [CONTACT_106099], Inc. [ADDRESS_765200] Lafayette, IN  [ZIP_CODE] 
[LOCATION_003] . 
Table  21 Pharmacokinetic Sample Schedule  
Collection Time  Day 1  – First Dose  EOIV  – Last Dose  a 
Predose at 0 minutes  X X 
End of  infusion , 57 to 60 minutes  after infusion start  X X 
1.5 to 3 hours after  infusion  start X X 
4 to 6 hours after  infusion  start X X 
12 hours after  infusion start  X X 
End of second infusion , 57 to 60 minutes after 
infusion start  X Not Applicable  
EOIV = end of intravenous  
a Participants received an IV infusion for at least 3 days  (6 doses)  up to [ADDRESS_765201] time point or to infinity  
β-HCG  beta-human chorionic gonadotropin  
bid twice daily  
CD4  cluster of differentiation 4  
CI confidence interval  
CL clearance  
Cmax  maximum concentration  
D5W  5% dextrose injection  
ECG  electrocardiogram  
eCRF  electronic case report form  
EOIV  end of IV  
EOT  end of treatment  
GCP  good clinical practice  
HIV human immunodeficiency virus  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
I&D incision and drainage  
IRB Institutional Review Board  
ITT intent -to-treat 
IV intravenous(ly)  
IWRS  Interactive web response system  
Lesion response  percent reduction in lesion size ≥20% compared with baseline  
LTFU  long-term follow -up 
MedDRA  Medical Dictionary of Regulatory Activities  
mITT  modified  intent -to-treat 
micro -ITT microbiologic intent -to-treat 
MRSA  methicillin -resistant Staphylococcus aureus  
PI [INVESTIGATOR_581880]  
q12h  every 12 hours  
q24h every 24 hours  
QTcF  QT interval calculated with Fridericia ’s correction formula  
SAE  serious adverse event  
SAP statistical analysis plan  
SAR  suspected adverse reaction  
S[LOCATION_003]R  suspected unexpected serious adverse reactions  
t½  terminal half -life 
tmax time to maximal concentration  
Vz  volume of distribution  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 76 
 
  10.7 Contraceptive Guidance and Collection of Pregnancy Information  
Definitions:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until she is postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.  
Women in the following categ ories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
1. Documented hysterectomy  
Documented bilateral salpi[INVESTIGATOR_581881] c ause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determine study entry. Documentation can come from the site personnel’s review 
of the participant’s medical records, medical examinati on, or medical history interview.  
3. Postmenopausal female  
1. A postmenopausal state is defined as no menses for [ADDRESS_765202] discontinue horm one replacement 
therapy to allow confirmation of postmenopausal status before study enrollment.  
 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 77 
 
  Collection of Pregnancy Information  
Male participants with partners who become pregnant  
• The investigator will attempt to collect pregnancy information on any m ale participant’s 
female partner who becomes pregnant while the male participant is in this study.  
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the ap propriate form and 
submit it to the sponsor within 24  hours after learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded t o the sponsor. 
Generally, the follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedu re. 
 
Female Participants who become pregnant  
The investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. Information will be recorded on the Pregnancy 
Report Form and submitted to the sponsor within 24 hours after learning of a participant's 
pregnancy.  
• Study medication should be stopped immediately.  
• Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study.  
• The investi gator should counsel the participant regarding the possible effects of prior 
study medication exposure on the fetus and the need to inform the study site of the 
outcome of the pregnancy.  
• The participant will be followed to determine the outcome of the preg nancy. The 
investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, follow -up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. A ny termination of 
pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) 
or indication for the procedure. The Pregnancy Report Form  will be used to follow -up the 
outcome of the pregnancy . 
• While pregnancy itself is not con sidered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or SAE. A 
spontaneous abortion is always considered to be an SAE and will be reported as such. 
Any poststudy pregnancy -related SAE consi dered reasonably related to the study 
intervention by [CONTACT_79982]  8.3.5 . While the inve stigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 78 
 
  11 REFERENCES  
1. Arciola C R, Campoccia D, Montanaro L. Implant infections: adhesion, biof ilm formation 
and immune evasion. Nature Reviews/Microbiology. 2018; 
https://doi.org/10.1038/s41579 -018-0019 -y. 
2. Avelox® [prescribing information]. Wayne, NJ. Bayer Healthcare Pharmaceuticals Inc., 
September 2016.  
3. Centers for Disease Control and Prevention.  Antibiotic resistance threats in the United 
States, 2013 (report). US Department of Health and Human Services, 2013. Available at 
http://www.cdc.gov/drugresistance/threat -report -2013/ . Accessed  [ADDRESS_765203]  2018.  
4. Chaisson  RE. Treatment of chronic infections with rifamycins: Is resistance likely to 
follow? Antimicrob Agents Chemther. 2003;47(10):3037 –3039.  
5. Clopper C J, Pearson ES. The use of confidence or fiducial limits illustrate d in the case of 
the binomial. Biometrika. 1934;26:404 –413. 
6. Food and Drug Adminis tration, Center for Drug Evaluation and Research. Guidance for 
Industry —Acute Bacterial Skin and Skin Structure Infections: Developi[INVESTIGATOR_234112]. Oct 2013. Available at: 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf  
7. Infusion Nurs es Society. Infusion nursing standards of practice, Phlebitis Scale. J Infus 
Nurs 2011;34(1S):S65.  
8. Ma Z, Lynch AS. Development of a dual -acting antibacterial a gent (TNP -2092) for the 
treatment of persistent bacterial infec tions. J Med Chem. 2016;59:6645 –6657. 
9. Miettinen O S, Nurminen M M. Comparative analysis of two rates. Statistics in Medicine. 
1985; 4 (2):213 –226. 
10. Pace JL,  Rupp  ME, Finch RG. Biofilms, infection, and antimicrobial therapy . Boca 
Raton, FL CRC Press; 2006 . 
11. Rifadin  IV [prescribing information].  Bridgewater, NJ: [COMPANY_011] -Aventis, 201 9. 
12. Robertson GT, Bonventre EJ, Doyle TB et al. In vitro evaluation of CBR -2092, a novel 
rifamycin -quinolone hybrid a ntibiotic: St udies of the mode of a ction in Staphylococcus 
aureus. Antimi crob. Agents Chemother. 2008;52 (7):2313 –2323.  
13. Robertson GT, Bonventre EJ, Doyle TB et al. In vitro evaluation of CBR -2092, a novel 
rifamycin -quinolone hybrid antibiotic: Studies of the mode of a ction in Staphylococcus 
aureus. Antimicrob. Agents Chemother. 2008;52 (7):2324 –2334 . 
14. Tande AJ, Patel R. Prosthetic Joint Infection. Clinical Microbiology Reviews. 
2014;27(2):302 –345. 
TNP -2092  TenNor Therapeutics Ltd.  
Protocol PJI001 -02 Page 79 
 
  15. TenNor Therapeutics  Limited.  Investigator’s Brochure. TNP -2092. Edition 2.0. 
September 2018 .  
16. Vancomycin [prescribing information]. Lake Forest, IL: Hospi[INVESTIGATOR_20116], 2018.  
17. Van Hal SJ, Peterson DL. New gram -positive antibiotics: Better than vancomycin? Curr 
Opin Infect Dis. 2011;24:515 –520. 
18. Waldvogel,  FA, Bisno, AL. Molecular basis of adherence of Staphylococcus aureus to 
biomaterials. In Waldvogel, FA, Bisno, AL eds.  Infections Associated with Indwelling 
Medical Devices.  3rd ed. Washington, DC: ASM P ress;2000:27 –39. 